[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 166
1. Takemura Y, Ikeda M, Kobayashi K, Nakazawa Y, Mori Y, Mitsuishi T, Ishigame H, Kameko F, Fujita K, Ichinohasama R: Plasma cell leukemia producing monoclonal immunoglobulin E. Int J Hematol; 2009 Oct;90(3):402-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia producing monoclonal immunoglobulin E.
  • A 78-year-old male with lumbar pain and dim consciousness presented the clinical pictures of plasma cell leukemia (PCL) producing a large amount of monoclonal immunoglobulin E (IgE)/kappa protein.
  • Circulating plasma cells demonstrated CD19(-)/CD56(-) and MPC-1(-)/CD49e(-)/CD45(+/-), the latter indicating the immature phenotype of the tumor cells.
  • Bone marrow was occupied with immature, atypical plasma cells, of which cytoplasms were positive for IgE by direct immunofluorescence analysis.
  • The clinical and biological characteristics of IgE-producing PCL, a very rare type of plasma cell dyscrasia, are discussed, reviewing the past literature.
  • [MeSH-major] Antibodies, Monoclonal / blood. Bone Neoplasms / immunology. Immunoglobulin E / blood. Immunoglobulin kappa-Chains / blood. Leukemia, Plasma Cell / immunology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2006 Jan;83(1):39-43 [16443550.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Scand J Clin Lab Invest. 1999 Oct;59(6):451-6 [10612556.001]
  • [Cites] Blood. 1993 Feb 1;81(3):767-74 [8427968.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):262-4 [8296801.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):353-7 [17378894.001]
  • [Cites] Pathology. 2003 Feb;35(1):87-9 [12701695.001]
  • [Cites] Postgrad Med J. 1983 Dec;59(698):784-5 [6657539.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1976 Dec;39(6):862-75 [1037461.001]
  • [Cites] Blood. 1990 Jul 15;76(2):377-82 [1695113.001]
  • [Cites] Br J Haematol. 2004 Apr;125(1):38-41 [15015966.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1570-1 [12393502.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):131-40 [10233376.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2195-202 [12200385.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2484-91 [15187021.001]
  • [Cites] J Clin Lab Immunol. 1979 Nov;2(4):343-8 [119859.001]
  • [Cites] Acta Haematol. 2007;118(3):178-82 [17934254.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3887-97 [9808582.001]
  • [Cites] Br J Haematol. 1992 Jul;81(3):331-5 [1382543.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):298-305 [18231917.001]
  • [Cites] Clin Chim Acta. 1988 Aug 31;176(2):151-6 [3180463.001]
  • [Cites] Mol Cell. 1999 Jan;3(1):119-23 [10024885.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):597-603 [10048434.001]
  • [Cites] Immunology. 1967 Oct;13(4):381-94 [4168094.001]
  • [Cites] N Engl J Med. 1969 Nov 27;281(22):1217-20 [4186803.001]
  • [Cites] Panminerva Med. 1996 Sep;38(3):179-84 [9009684.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):637-8 [19064952.001]
  • (PMID = 19728026.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin kappa-Chains; 37341-29-0 / Immunoglobulin E
  • [Number-of-references] 28
  •  go-up   go-down


2. Abe M, Yokoyama H, Tohmiya Y, Okitsu Y, Ohguchi H, Kohata K, Yamamoto J, Onishi Y, Ishizawa K, Kameoka J, Harigae H: Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy. Intern Med; 2009;48(20):1833-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy.
  • Plasma cell leukemia (PCL) is a rare variant of multiple myeloma, which is very aggressive and resistant to chemotherapy.
  • We report a case of PCL successfully treated with syngeneic peripheral blood stem cell transplantation followed by low-dose thalidomide.
  • The clinical course of the present case suggests that autologous stem cell transplantation using a graft with reduced contamination of malignant cells followed by low-dose thalidomide maintenance therapy may improve the PCL treatment outcome.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Stem Cell Transplantation. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834277.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


3. Wandroo FA, Mahendra P, Khuroo RA, Neilson J: Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions. Clin Lab Haematol; 2005 Jun;27(3):203-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions.
  • The patient was subsequently diagnosed to have plasma cell leukaemia.
  • The most common sites of bony involvement in plasma cell dyscrasia are skull, vertebrae, ribs and long bones.
  • Although it is quite unusual for plasma cell leukaemia or myeloma to involve solely small joints of hands and feet, we suggest plasma cell dyscrasia should be kept in the differential diagnostic list for polyarthralgia in adults if usual causes are ruled out.
  • [MeSH-major] Arthralgia / complications. Fingers / pathology. Foot / pathology. Leukemia, Plasma Cell / complications. Osteolysis / pathology

  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938728.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Bang HI, Yoo JY, Kim KH, Park R, Shin JW, Choi TY, Lee SC, Park HS, Won JH: [A case of central nervous system myelomatosis with complex chromosome aberrations]. Korean J Lab Med; 2010 Aug;30(4):334-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma cells were found in the cerebrospinal fluid (CSF), and CSF immunoelectrophoresis revealed abnormal precipitin arcs against anti-IgG and anti-lambda antisera.
  • She was given systemic chemotherapy and eight courses of intrathecal chemotherapy, which cleared plasma cells in the CSF.
  • Two months later, she was given autologous stem cell transplantation.
  • Three months after stem cell transplantation, central nervous system myelomatosis progressed to plasma cell leukemia and two months later, the patient expired.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Chromosome Deletion. Multiple Myeloma / diagnosis. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Disease Progression. Female. Gene Deletion. Humans. Immunoelectrophoresis. In Situ Hybridization, Fluorescence. Leukemia, Plasma Cell / diagnosis. Middle Aged. Plasma Cells / pathology. Precipitins / metabolism. Receptor, Fibroblast Growth Factor, Type 3 / genetics. Stem Cell Transplantation. Transplantation, Autologous. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805703.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Precipitins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


5. Thu GO, Hem LY, Hansen S, Møller B, Norstein J, Nøkleby H, Grotmol T: Is there an association between SV40 contaminated polio vaccine and lymphoproliferative disorders? An age-period-cohort analysis on Norwegian data from 1953 to 1997. Int J Cancer; 2006 Apr 15;118(8):2035-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to examine Norwegian cancer incidence data to assess a possible association between birth cohorts assumed to have been subjected to the vaccine and the incidence rate of lymphoproliferative disorders (excluding Hodgkin's lymphoma), further subdivided into non-Hodgkin's lymphoma (NHL), lymphocytic leukemia and plasma cell neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287082.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Poliovirus Vaccines
  •  go-up   go-down


6. Ataergin S, Arpaci F, Kaya A, Cetin T, Gunhan O: VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol; 2006 Dec;81(12):987-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Boronic Acids / administration & dosage. Leukemia, Plasma Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Protease Inhibitors / administration & dosage. Pyrazines / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Hematol. 2007 Jan;82(1):89. Kaya, Turker [corrected to Cetin, Turker]
  • (PMID = 16888783.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; VAD combination
  •  go-up   go-down


7. Gertz MA, Buadi FK: Plasma cell leukemia. Haematologica; 2010 May;95(5):705-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia.
  • [MeSH-major] Leukemia, Plasma Cell / mortality. Leukemia, Plasma Cell / surgery
  • [MeSH-minor] Humans. Plasma Cells. Stem Cell Transplantation / mortality. Stem Cell Transplantation / trends. Survival Rate / trends

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Haematologica. 2010 May;95(5):804-9 [20442444.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):351-4 [11999568.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):362-7 [12185504.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Clin Lab Haematol. 2004 Feb;26(1):37-42 [14738436.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2837-40 [15976175.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Acta Oncol. 2007;46(2):262-4 [17453381.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1423-5 [17613775.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1153-6 [18083228.001]
  • [Cites] Leukemia. 2008 May;22(5):1044-52 [18216867.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):624-36 [19396865.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5734-9 [19877113.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):e104-5 [19889456.001]
  • [CommentOn] Haematologica. 2010 May;95(5):804-9 [20442444.001]
  • (PMID = 20442443.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864374
  •  go-up   go-down


8. de Larrea CF, Cibeira MT, Vallansot R, Colomo L, Bladé J: Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma; 2008 Oct;8(5):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
  • 73-year-old woman complaining of bone pain and weight loss was suspected to have a malignant disease, and extensive laboratory investigations were carried out.
  • She was diagnosed with multiple myeloma; however, because of the finding of extremely high serum levels of CA125 and CA15.3 and focal liver lesions, a concomitant solid tumor was suspected, which was then excluded with the appropriate tests, including an ultrasound-guided liver biopsy.
  • While being diagnosed, the patient developed a rapidly evolving plasma cell leukemia with a simultaneous increase in CA125 and CA15.3.
  • After treatment with cyclophosphamide and dexamethasone, the peripheral blood plasma cells disappeared and there was a dramatic decrease in the CA125 and CA15.3 tumor markers.
  • High levels of the latter can be observed in patients with aggressive plasma cell dyscrasias, an observation that is crucial in order to avoid unnecessary tests that can result in treatment delay.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Leukemia, Plasma Cell / blood. Mucin-1 / blood

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854288.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Mucin-1; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D: Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer; 2009 Dec 15;115(24):5734-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004.
  • BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients.
  • The median overall survival (OS) was 4 months and the median disease-specific survival (DSS) was 6 months for patients with PCL; the 1-year, 2-year, and 5-year OS rates were 27.8%, 14.1%, and 6.4%, respectively.
  • [MeSH-major] Leukemia, Plasma Cell / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multiple Myeloma / mortality. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19877113.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kumar S, Kimlinger T, Morice W: Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol; 2010 Sep;23(3):433-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping in multiple myeloma and related plasma cell disorders.
  • Plasma cell disorders form a spectrum ranging from the asymptomatic presence of small monoclonal populations of plasma cells to conditions like plasma cell leukemia and multiple myeloma, in which the bone marrow can be replaced by the accumulation of neoplastic plasma cells.
  • Immunophenotyping has become an invaluable tool in the management of hematological malignancies and is increasingly finding a role in the diagnosis and monitoring of plasma cell disorders.
  • This, along with a better understanding of the phenotypic heterogeneity of the clonal plasma cells in different disorders, has made immunophenotyping an indispensible tool in the diagnosis, prognostic classification and management of plasma cell disorders.
  • This book chapter addresses the approaches taken to evaluate monoclonal plasma cell disorders, and the different markers and techniques that are important for the study of these diseases.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2006 Dec 15;108(13):4194-7 [16946299.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5002-10 [17311991.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):951-5 [17550325.001]
  • [Cites] Leukemia. 2007 Sep;21(9):2043-6 [17460704.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2586-92 [17576818.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(11):1033-7 [17891186.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):298-305 [18231917.001]
  • [Cites] Semin Immunol. 2008 Feb;20(1):49-58 [18222702.001]
  • [Cites] Haematologica. 2008 Mar;93(3):431-8 [18268286.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):379-82 [17767956.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3403-6 [18216299.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2737-44 [18443352.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4017-23 [18669875.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):882-5 [12060125.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3095-100 [12384404.001]
  • [Cites] Blood. 2003 Feb 1;101(3):827-30 [12393530.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):36-43 [12670329.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3136-41 [12480692.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Immunol Rev. 2003 Aug;194:105-11 [12846811.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1070-1 [12702507.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1075-7 [12714489.001]
  • [Cites] Amyloid. 2003 Jun;10(2):110-6 [12964418.001]
  • [Cites] Blood Cells Mol Dis. 2004 Mar-Apr;32(2):293-301 [15003821.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Haematologica. 2004 May;89(5):547-51 [15136217.001]
  • [Cites] Br J Haematol. 2004 Sep;126(5):665-74 [15327517.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2281-9 [15512818.001]
  • [Cites] Br J Haematol. 1968 Oct;15(4):417-20 [4176071.001]
  • [Cites] Blood. 1980 Mar;55(3):364-72 [7357075.001]
  • [Cites] J Clin Pathol. 1982 Jan;35(1):63-8 [6801095.001]
  • [Cites] Blood. 1983 Jul;62(1):166-71 [6407546.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):807-16 [19287458.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):724-30 [19638544.001]
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):60-6 [19864234.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1599-602 [19880781.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4369-72 [19755674.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):110-4 [19821821.001]
  • [Cites] Br J Haematol. 2010 May;149(3):334-51 [20201947.001]
  • [Cites] Haematologica. 2010 Jun;95(6):1016-20 [20081059.001]
  • [Cites] Cytometry B Clin Cytom. 2010 Jul;78(4):239-52 [20155853.001]
  • [Cites] Cytometry. 1999 Dec 15;38(6):286-92 [10589044.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3096-104 [10850462.001]
  • [Cites] Blood. 2001 Jul 1;98(1):187-93 [11418479.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):957-62 [11753551.001]
  • [Cites] J Immunol Methods. 1991 Nov 22;144(2):253-6 [1683667.001]
  • [Cites] Ann Hematol. 1992 Mar;64(3):132-9 [1373957.001]
  • [Cites] Aust N Z J Med. 1992 Jun;22(3):291-302 [1497556.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3382-7 [8507875.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):108-13 [8508395.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2597-603 [7522634.001]
  • [Cites] Br J Haematol. 1994 Jun;87(2):266-72 [7947266.001]
  • [Cites] Blood. 1995 Jan 15;85(2):436-47 [7529064.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3647-53 [7543019.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1780-7 [8781435.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):113-20 [8817086.001]
  • [Cites] Br J Haematol. 1996 Dec;95(3):489-93 [8943889.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1521-6 [9626472.001]
  • [Cites] Leukemia. 2002 Jan;16(1):135-43 [11840273.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):273-7 [11841427.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2172-8 [11877294.001]
  • [Cites] Am J Hematol. 1985 Nov;20(3):289-92 [3904417.001]
  • [Cites] Mayo Clin Proc. 1987 Nov;62(11):969-77 [3118117.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1041-6 [3286829.001]
  • [Cites] Blood. 1988 Jul;72(1):219-23 [3291982.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):859-62 [2914294.001]
  • [Cites] Blood. 1990 Jul 15;76(2):377-82 [1695113.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1739-47 [2224123.001]
  • [Cites] Br J Haematol. 1991 Feb;77(2):185-90 [1706197.001]
  • [Cites] Clin Exp Immunol. 1991 Mar;83(3):418-22 [1706237.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3887-97 [9808582.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1821-8 [9823960.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):131-7 [10027725.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):138-43 [10027726.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):121-31 [10520032.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):230-42 [15738953.001]
  • [Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]
  • [Cites] Haematologica. 2005 Apr;90(4):489-93 [15820944.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):961-6 [15978948.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5668-74 [16110026.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1300B [16219557.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1365-72 [16219573.001]
  • [Cites] Leukemia. 2005 Nov;19(11):2021-2 [16167057.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):168-70 [16398651.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Br J Haematol. 2006 Jun;133(5):530-2 [16681641.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):693-703 [16706268.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):14-8 [16827882.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):545-51 [16938662.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):741-50 [16977339.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1577-8 [17043027.001]
  • (PMID = 21112041.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-10; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS246587; NLM/ PMC3005703
  •  go-up   go-down


11. Guglielmelli T, Merlini R, Giugliano E, Saglio G: Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol; 2009;2009:867380
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia.
  • Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the presence of a peripheral blood absolute plasma cell count of at least 2 x 109/l and more than 20% circulating plasma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2008 Nov;20(6):697-704 [18841053.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1637-8 [18433866.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2962-72 [18332230.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1805-10 [17875806.001]
  • (PMID = 20011654.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2786165
  •  go-up   go-down


12. Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE: Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol; 2006 Oct;10(5):263-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.
  • Plasma cell leukemia (PCL) is a neoplastic disorder of plasma cells of which there are 2 forms, primary PCL and secondary PCL, the latter occurring in patients with a history of plasma cell myeloma.
  • In all cases, the bone marrow aspirate smears and biopsy specimens demonstrated a diffuse infiltrate of atypical plasma cells that were difficult to classify using morphologic criteria alone.
  • Immunophenotypic studies showed that each case was positive for plasma cell-associated antigens (cytoplasmic immunoglobin, CD38, or CD138) and negative for CD20.
  • Despite chemotherapy and the use of novel therapeutic agents and stem cell transplantation, all 4 patients had short survival.
  • [MeSH-major] Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / pathology. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD38 / metabolism. Bone Marrow / pathology. Combined Modality Therapy. Female. Humans. Immunophenotyping. Karyotyping. Male. Membrane Glycoproteins / metabolism. Middle Aged. Plasma Cells / immunology. Plasma Cells / pathology. Proteoglycans / metabolism. Survival Analysis. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979517.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


13. Buda G, Carulli G, Orciuolo E, Cannizzo E, Zucca A, Azzarà A, Rossi A, Galimberti S, Cecconi N, Petrini M: Two cases of plasma cell leukemia with atypical immunophenotype. Acta Haematol; 2007;118(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of plasma cell leukemia with atypical immunophenotype.
  • [MeSH-major] Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / immunology. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology
  • [MeSH-minor] Antigens, CD / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Fatal Outcome. Female. Flow Cytometry. Humans. Immunophenotyping. Middle Aged. Risk Assessment. Severity of Illness Index

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429194.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


14. Rao PS, Shenoy KK, Rai S: Plasma cell leukemia with ovarian serous cystadenocarcinoma. Indian J Pathol Microbiol; 2007 Jul;50(3):663
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia with ovarian serous cystadenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Leukemia, Plasma Cell / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Indian J Pathol Microbiol. 2003 Jul;46(3):446-7 [15025299.001]
  • (PMID = 17883177.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] India
  •  go-up   go-down


15. Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J: Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biol Blood Marrow Transplant; 2009 Jun;15(6):686-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
  • The objective of this study is to describe presenting features and outcomes of patients < or =40 years of age with MM who undergo autologous stem cell transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free survival (PFS) to patients aged 41-65 years.
  • We performed a retrospective institutional review of all patients < or =40 years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from January 1, 1990, to July 31, 2007.
  • There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the reported rate of 2%-4%.
  • At diagnosis, there was an increased rate of renal failure in the young cohort compared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Incidence. Kaplan-Meier Estimate. Leukemia, Plasma Cell / epidemiology. Male. Middle Aged. Neoplasms, Second Primary / epidemiology. Postoperative Complications / epidemiology. Prognosis. Renal Insufficiency / epidemiology. Renal Insufficiency / etiology. Retrospective Studies. Survival Rate. Transplantation Conditioning / methods. Transplantation Conditioning / statistics & numerical data. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450753.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW: Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res; 2009 Aug 1;15(15):4847-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
  • AdEHCD40L inhibited MM cell growth more effectively than AdEHNull.
  • AdEHCD40L induced apoptosis and S-phase cell cycle blockade while uniquely up-regulating the previously described proapoptotic elements tumor necrosis factor-related apoptosis-inducing ligand, Fas, and IL-8.
  • The direct growth-inhibitory activity of AdEHCD40L, together with the well-known immune-potentiating features of CD40L, may be clinically applicable for the experimental treatment of MM or plasma cell leukemia.
  • [MeSH-minor] Adenoviridae Infections / virology. Animals. Apoptosis / physiology. Cell Cycle / physiology. Cell Line, Tumor. Cytokines / metabolism. Humans. Mice. Mice, SCID. Oligonucleotide Array Sequence Analysis. Proteomics. Transduction, Genetic. Transgenes / genetics. Transgenes / physiology. Xenograft Model Antitumor Assays


17. Ohno H, Tanaka H, Sakai H, Katsurada T, Yoshida Y: Polyclonal proliferation of plasma cells associated with marked hypergammaglobulinemia in an elderly patient. Int J Hematol; 2005 Jan;81(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyclonal proliferation of plasma cells associated with marked hypergammaglobulinemia in an elderly patient.
  • We describe an 89-year-old woman who presented with prominent plasmacytosis mimicking plasma cell leukemia.
  • The plasma cells in the peripheral blood expressed polyclonal surface/cytoplasmic immunoglobulins as well as CD19, CD30, CD38, and CD138 antigens but lacked CD10, CD20, CD25, and CD56.
  • The bone marrow plasma cells showed the CD45+, CD19+, CD56-, MPC-1(-/+), and CD49e- immunophenotype, which was in clear contrast with the immunophenotypes of the neoplastic myeloma cells.
  • Abdominal lymphadenopathy, splenomegaly, and a high level of soluble interleukin 2 receptor may have been reflections of an underlying lymphoproliferative disorder, potentially leading to the polyclonal proliferation of plasma cells.
  • [MeSH-major] Hypergammaglobulinemia / immunology. Hypergammaglobulinemia / pathology. Plasma Cells / cytology
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division / immunology. Fatal Outcome. Female. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2045-56 [8161776.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):379-80 [12688365.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1026-7 [12873179.001]
  • [Cites] Acta Haematol. 1998;99(2):57-64 [9554450.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1620-7 [7564499.001]
  • [Cites] Blood. 1989 Sep;74(4):1360-7 [2788466.001]
  • [Cites] Mayo Clin Proc. 2001 May;76(5):476-87 [11357794.001]
  • [Cites] Blood. 1999 Jul 15;94(2):701-12 [10397737.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2000;:133-146 [11701539.001]
  • (PMID = 15717691.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Marionneaux S, Monsalve B, Plante N, Shulman S, Vega AM: The application of Beckman Coulter VCS technology at a major cancer center, with emphasis on the detection of circulating immature plasma cells in plasma cell leukemia. Lab Hematol; 2006;12(4):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of Beckman Coulter VCS technology at a major cancer center, with emphasis on the detection of circulating immature plasma cells in plasma cell leukemia.
  • Circulating plasma cells are not a common finding in multiple myeloma.
  • Being able to detect plasma cells in peripheral blood is important because they are a prognostic indicator that correlates with disease progression.
  • Furthermore, the peripheral blood plasma cell population can demonstrate morphologic variability.
  • Immature plasma cells, both plasmablasts and proplasmacytes are associated with more aggressive disease and shortened survival.
  • We encountered 3 multiple myeloma patients with circulating immature plasma cells that appeared as distinct populations on our hematology analyzer's automated white blood cell (WBC) differential.
  • The immature plasma cells, given their unique cellular characteristics, appeared in a common place within the WBC differential scatterplot in each patient.
  • In our laboratory, we have utilized this common graphic pattern to screen for immature plasma cells.
  • We have also used examination of the scatterplots in other hematologic malignancies such as chronic lymphocytic leukemia.
  • [MeSH-major] Data Display. Flow Cytometry / instrumentation. Leukemia, Plasma Cell / diagnosis. Leukocyte Count / instrumentation. Multiple Myeloma / immunology. Plasma Cells / classification

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118772.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Hirase N, Muta S, Abe Y, Muta K: [Plasma cell leukemia presenting with cleaved nuclei and a monocytoid appearance]. Rinsho Ketsueki; 2007 Jan;48(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukemia presenting with cleaved nuclei and a monocytoid appearance].
  • A 74-year-old man presented with anemia, thrombocytopenia and leukocytosis with 41% abnormal cells having cleaved and monocytoid nuclei.
  • The bone marrow was infiltrated with 43.6% abnormal cells that were negative for peroxidase staining and positive for PAS staining.
  • Immunostaining also revealed expression of IgA and kappa-type in the abnormal cells.
  • The patient was diagnosed as having plasma cell leukemia but the morphological findings were unusual.
  • This case suggests that immunostaining of abnormal cells is required for the differential diagnosis of plasma cell leukemia in leukocytosis.
  • [MeSH-major] Cell Nucleus / pathology. Leukemia, Plasma Cell / pathology
  • [MeSH-minor] Aged. Antigens, CD38 / biosynthesis. Diagnosis, Differential. Humans. Leukocytosis / pathology. Male

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313079.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


20. Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H, Robillard N, Harousseau JL, Bataille R, Moreau P: Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications. Leuk Lymphoma; 2007 Jan;48(1):207-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Plasmacytoma / diagnosis. Plasmacytoma / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325872.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


21. Brück P, Mousset S, Bühme A, Hoelzer D, Atta J: Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol; 2007 Jul;86(1):66-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
  • Primary plasma cell leukemia (PCL) is a rare hematologic disorder with distinct features.
  • The criterion for the diagnosis of PCL is based on the finding of malignant plasma cells in the peripheral blood (more than 2 x 10(9)/L or more than 20% of white blood cells).
  • Examination of blood smears led to the diagnosis of PCL, which was confirmed by bone marrow biopsy.
  • After an oral induction chemotherapy consisting of cyclophosphamide and high dose dexamethasone followed by one cycle of high-dose dexamethasone and thalidomide no evidence of the disease in the peripheral blood was detectable.
  • Six months after first diagnosis, the patient was found to have bone marrow and peripheral blood relapse with anemia and neutropenia in the clinical context of acute on chronic renal failure.
  • After a limited response to further chemotherapy, the patient died 14 months after the first diagnosis while on dexamethasone maintenance.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):901-4 [9404934.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):351-4 [11999568.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1067-73 [12148888.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):262-4 [8296801.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):607-12 [11740818.001]
  • [Cites] Eur J Haematol. 2001 Jul;67(1):51-3 [11553267.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Transplant Proc. 2002 Nov;34(7):2929-30 [12431661.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):119-23 [11907796.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Leuk Res. 2001 Feb;25(2):103-7 [11166824.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):362-7 [12185504.001]
  • [Cites] Ann Hematol. 1999 Jan;78(1):25-7 [10037265.001]
  • (PMID = 17675269.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


22. Pretz J, Medeiros BC: Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. Am J Hematol; 2009 Oct;84(10):698-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
  • [MeSH-major] Antineoplastic Agents. Leukemia, Plasma Cell / drug therapy. Pulmonary Eosinophilia / chemically induced. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691102.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


23. Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S: Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol; 2008;25(2):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirty patients with primary plasma cell leukemia: a single center experience.
  • The primary plasma cell leukemia (PCL) is a rare aggressive plasma cell dyscrasia.
  • All patients had anemia, thrombocytopenia, circulating plasma cells (median count 4 x 10(9)/l), and in 18/30 patients hypercalcemia was found.
  • The plasma cells were CD138+ and CD38+ (9/9), CD20+ (1/9), and CD10+ (1/9) with cytoplasmic positivity for light chains (9/9).
  • The immunologic and cytogenetic presentation of patients with PCL bears little significance on prognosis, which is heavily compromised by advanced age at diagnosis and the poor performance status.
  • [MeSH-major] Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Blood. 1978 Oct;52(4):839-45 [687831.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):109-14 [8019953.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Curr Treat Options Oncol. 2001 Jun;2(3):205-16 [12057120.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4269-78 [9834233.001]
  • [Cites] Leukemia. 2005 Apr;19(4):659-63 [15716988.001]
  • [Cites] Leukemia. 1998 Jun;12(6):960-9 [9639426.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] J Maine Med Assoc. 1977 Oct;68(10):350-1 [908884.001]
  • [Cites] Blood. 1997 Jul 15;90(2):526-34 [9226151.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Blood. 1982 Oct;60(4):851-5 [7115956.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • (PMID = 18488157.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B: Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res; 2009 Feb;33(2):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare form of plasma cell malignancy, few large series reported underlying genetic abnormalities.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetics Home Reference. consumer health - chromosome 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676019.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Ali R, Beksac M, Ozkalemkas F, Ozkocaman V, Ozkan A, Ozcelik T, Tunali A: Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma; 2007 Jul;48(7):1426-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
  • [MeSH-major] Boronic Acids / therapeutic use. Leukemia, Plasma Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • (PMID = 17613776.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


26. Capalbo S, Chiefa A, Delia M, Diomede D, Liso V: Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol; 2007;46(2):262-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Dexamethasone / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453381.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


27. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K: Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res; 2008 Jul;32(7):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
  • Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasias.
  • Its special biological characteristics may play an important role in the poor outcome when treated with conventional therapy or even with stem cell transplantation.
  • New treatment approaches based on the biology of this disease are mandatory.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Dexamethasone / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083228.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


28. Gulati A, Kaushik R: Plasma cell leukaemia. Indian J Pathol Microbiol; 2007 Jan;50(1):91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukaemia.
  • [MeSH-major] Blood Cells / cytology. Bone Marrow / pathology. Leukemia, Plasma Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474272.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


29. Lü SQ, Yang JM, Wang JM: [Effects of proteasome inhibitors on leukemias]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):896-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of proteasome inhibitors on leukemias].
  • The abnormality of its activity is sign of tumorigenesis.
  • A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708829.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 27
  •  go-up   go-down


30. Jameel A: Plasma cell leukemia: case report of a rare and aggressive variant of multiple myeloma. J Pak Med Assoc; 2005 Oct;55(10):452-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: case report of a rare and aggressive variant of multiple myeloma.
  • Plasma cell leukemia (PCL) is a rare disease and is the least common variant of multiple myeloma accounting for 2-3% of all plasma cell dyscrasias.
  • Initial evaluation revealed plasmacytosis with blood plasma cell count of 5184/cumm.
  • His hemoglobin (Hb) was 11.3 gm/dl, platelets were 75000/cumm and total leucocyte count (TLC) was 21600/cumm (24% plasma cells).
  • A diagnosis of PCL was made and the patient was started on treatment for hypercalcaemia with Melphalan/Prednisolone regime along with supportive care.
  • [MeSH-major] Leukemia, Plasma Cell / etiology. Multiple Myeloma / complications
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Drug Therapy, Combination. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Leukocyte Count. Male. Melphalan / therapeutic use. Middle Aged. Plasma Cells / pathology. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304856.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


31. Dadu T, Rangan A, Handoo A, Bhargava M: Primary non-secretory plasma cell leukemia with atypical morphology - a case report. Indian J Hematol Blood Transfus; 2009 Jun;25(2):81-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-secretory plasma cell leukemia with atypical morphology - a case report.
  • Only one case of primary non-secretory plasma cell leukemia with atypical morphology has been reported thus far.
  • Here we report another such case of plasma cell leukemia diagnosed on fl ow cytometry, as morphological heterogeneity and lack of monoclonal immunoglobulins in both serum and urine, made it difficult to come to a conclusive diagnosis based purely on morphology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1998 Sep;83(9):849-50 [9825580.001]
  • [Cites] Ann Hematol. 1999 Jan;78(1):25-7 [10037265.001]
  • [Cites] J Postgrad Med. 1998 Apr-Jun;44(2):47-9 [10703570.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):232-7 [12865467.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Oct;47(4):592-3 [16295407.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1212-5 [16879026.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):104-5 [15027746.001]
  • [Cites] J Leukoc Biol. 2004 Sep;76(3):528-36 [15155772.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1234-40 [16956823.001]
  • (PMID = 23100981.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452963
  • [Keywords] NOTNLM ; Electrophoresis / Flow cytometry / Multiple myeloma / Plasma cell leukemia
  •  go-up   go-down


32. Gertz MA: Managing plasma cell leukemia. Leuk Lymphoma; 2007 Jan;48(1):5-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing plasma cell leukemia.
  • [MeSH-major] Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • (PMID = 17325841.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


33. Sáez B, Martín-Subero JI, Lahortiga I, Largo C, Larrayoz MJ, Odero MD, Prosper F, Cigudosa JC, Siebert R, Calasanz MJ: Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes. Cancer Genet Cytogenet; 2007 May;175(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate this hypothesis, we have characterized the plasma cell leukemia cell line SK-MM2 and a primary myeloma both carrying simultaneous IGH-FGFR3/MMSET and IGH-CCND1 fusions as shown by multicolor fluorescence in situ hybridization.
  • Thus, biallelic IGH translocations might exert different pathogenetic effects in plasma cell disorders.
  • [MeSH-minor] Alleles. Cell Line. Chromosome Banding. Chromosome Painting. Cyclin D. Gene Expression Regulation, Neoplastic. Humans. Karyotyping. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498561.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Messenger; 0 / Repressor Proteins; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / WHSC1 protein, human; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


34. Kalyani R, Kumar ML: Plasma cell leukemia presenting as acute renal failure: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):86-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting as acute renal failure: a case report.
  • Plasma cell leukemia is a rare form of malignant plasma cell dyscrasia.
  • A case of primary plasma cell leukemia presenting as acute renal failure is reported here.
  • [MeSH-major] Acute Kidney Injury / etiology. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Blood Cells / cytology. Blood Proteins / analysis. Humans. Male. Middle Aged. Skull / radiography

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474270.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


35. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP Jr, Epner E: Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):464-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a study evaluating the presenting symptoms that led to the diagnosis of MM.
  • Ten categories of non-CRAB manifestations were found, in order of decreasing frequency: neuropathy (because of spinal cord compression, nerve root compression, or peripheral neuropathy), extramedullary involvement, hyperviscosity syndrome, concomitant amyloidosis (eg, nephrotic syndrome or cardiopathy), hemorrhage/coagulopathy, systemic symptoms (eg, fever or weight loss), primary plasma cell leukemia, infections, cryoglobulinemia, and secondary gout.
  • [MeSH-major] Anemia / pathology. Bone and Bones / pathology. Hypercalcemia / pathology. Multiple Myeloma / diagnosis. Renal Insufficiency / pathology
  • [MeSH-minor] Abnormalities, Multiple / classification. Abnormalities, Multiple / pathology. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Femur. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Syndrome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156463.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Kraj M, Sokołowska U, Kopeć-Szlezak J, Pogłód R, Kruk B, Woźniak J, Szpila T: Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma; 2008 Feb;49(2):298-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
  • The aim of this prospective, long-term study was to define the flow cytometric characteristics of plasma cell CD56 expression as well as determine the clinical characteristics of 204 multiple myeloma (MM) patients and 26 plasma cell leukemia (PCL) patients with regard to CD56 expression.
  • CD56 expression intensity was determined by measurement of antigen molecules on the cell defined as Antibodies Bound per Cell (ABC) and calculation of Relative Fluorescence Intensity (RFI).
  • The RFI values for individual MM patients ranged from 7.6 to 27.4 while ABC values on MM plasma cells from 2255 to 58469.
  • There was a correlation between the proportion of all bone marrow CD38(++)/CD138(+) cells with CD56 expression and ABC and RFI indices.
  • [MeSH-major] Antigens, CD56 / analysis. Multiple Myeloma / pathology. Plasma Cells / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Flow Cytometry. Humans. Leukemia, Plasma Cell / pathology. Longitudinal Studies. Male. Middle Aged. Osteolysis. Survival Rate

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231917.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


37. Hosono N, Yamauchi T, Nakamura T, Yamashita T, Ueda T: [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation]. Gan To Kagaku Ryoho; 2008 Mar;35(3):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
  • A 69-year-old Japanese man was diagnosed as having primary plasma cell leukemia.
  • His malignant plasma cells had a chromosomal translocation t(11;14)(q13;q32) that created overexpression of cyclin D1.
  • Thereafter, the patient received high-dose melphalan (125 mg/m(2)) followed by autologous peripheral blood stem cell transplantation.
  • Despite complete cytogenetic remission, the disease relapsed 6 months later, and the patient eventually died 16 months following the diagnosis.
  • Plasma cell leukemia is a rare hematological malignancy with a poor prognosis.
  • The present case suggested the effectiveness of the combination of hyper-CVAD and high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / surgery. Melphalan / therapeutic use. Peripheral Blood Stem Cell Transplantation


38. Austein T, Demme B: [80-year-old patient with dyspnoea, back ache and peripheral oedema. Plasma cell leukemia in multiple myeloma]. Dtsch Med Wochenschr; 2010 Nov;135(44):2187-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [80-year-old patient with dyspnoea, back ache and peripheral oedema. Plasma cell leukemia in multiple myeloma].
  • [Transliterated title] 80-jähriger Patient mit Dyspnoe, Rückenschmerzen und Beinödemen. Plasmazell-Leukämie bei multiplem Myelom. Plasmazell-Leukämie bei multiplem Myelom.
  • [MeSH-major] Back Pain / etiology. Dyspnea / etiology. Edema / etiology. Leg. Leukemia, Plasma Cell / diagnosis. Multiple Myeloma / diagnosis. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Plasma Cells / pathology


39. Nau KC, Lewis WD: Multiple myeloma: diagnosis and treatment. Am Fam Physician; 2008 Oct 1;78(7):853-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma: diagnosis and treatment.
  • The disease is diagnosed with serum or urine protein electrophoresis or immunofixation and bone marrow aspirate analysis.
  • Nuclear bone scans and dual energy x-ray absorptiometry have no role in the diagnosis and staging of myeloma.
  • The differential diagnosis of monoclonal gammopathies includes monoclonal gammopathy of uncertain significance, smoldering (asymptomatic) and symptomatic multiple myeloma, amyloidosis, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia, and rare plasma cell leukemia and heavy chain diseases.
  • Symptomatic multiple myeloma is treated with chemotherapy followed by autologous stem cell transplantation, if possible.
  • [MeSH-major] Multiple Myeloma / diagnosis. Multiple Myeloma / therapy
  • [MeSH-minor] Age Factors. Humans. Myeloma Proteins / physiology. Pain / etiology. Plasma Cells / physiology. Risk Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841734.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  • [Number-of-references] 29
  •  go-up   go-down


40. Sajid R, Moiz B, Kamran N, Adil SN: Pleural fluid plasmacytosis in a patient with plasma cell leukemia. Turk J Haematol; 2010 Jun 5;27(2):135-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural fluid plasmacytosis in a patient with plasma cell leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27263463.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


41. Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Iravani M, Bahar B, Khodabandeh A, Khatami F, Ghaffari F, Jalali A: Stem cell transplantation; Iranian experience. Arch Iran Med; 2009 Jan;12(1):69-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation; Iranian experience.
  • From March 1991 through 31st December 2007, 2042 patients underwent stem cell transplantation at the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences.
  • These transplantations included 1405 allogeneic stem cell transplantation, 624 autologous stem cell transplantation, and 13 syngeneic stem cell transplantation.
  • Stem cell transplantation was performed for various diseases including acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, thalassemia major, sickle cell thalassemia, sickle cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin's lymphoma, Hodgkin's disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combine immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms' tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis.
  • We had 105 cellular therapies for postmyocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, and renal cell carcinoma.
  • About 74.9% of the patients (1530 of 2042) remained alive between one to 168 months after stem cell transplantation.
  • Nearly 25.1% (512 of 2042) of our patients died after stem cell transplantation.
  • The causes of deaths were relapse, infections, hemorrhagic cystitis, graft versus host disease, and others.
  • [MeSH-major] Hematologic Neoplasms / surgery. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Iran Med. 2009 May;12(3):329. Alimogaddam, Kamran [corrected to Alimoghaddam, Kamran]; Mousavi, Seyed Asadollah [corrected to Mousavi, Seied Asadollah]
  • [ErratumIn] Arch Iran Med. 2012 Aug;15(8):524
  • (PMID = 19111033.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


42. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K: Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes; 2010;3:347
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.
  • BACKGROUND: Plasma microRNA (miRNA) has become a promising biomarker for detecting cancer; however, it remains uncertain whether miRNA expression levels in plasma reflect those in tumor cells.
  • Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for monitoring these patients.
  • RESULTS: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription polymerase chain reaction in 91 patients with acute leukemia.
  • We also determined miR-92a expression levels in peripheral blood mononuclear cells (PBMNC) from normal controls.
  • We compared miR-92a expression in plasma with its expression in leukemia cells.
  • Synthetic anti-miR-92a inhibitor was transfected into Raji and OM9;22 cells, and apoptosis was assessed.
  • For in vivo assessment, 6-week-old female nude mice were injected with U937 cells, and miR-92a expression in plasma and tumors was measured.
  • The level of miR-92a expression in fresh leukemia cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells obtained from healthy volunteers.
  • We also noticed that miR-92a was preferentially expressed in acute lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells.
  • More specifically, cellular miR-92a expression was significantly increased in a subset of ALL cells, and ALL patients with overexpressed miR-92a had poor prognoses.
  • The anti-miR-92a inhibitor-treated Raji and OM9;22 cells revealed an increase of apoptotic cells.
  • Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and ALL cells compared with PBMNC from healthy volunteers.
  • In tumor-bearing mice, the plasma miR-92a level was significantly decreased in accordance with tumor growth, while tumor tissue was strongly positive for miR-92a.
  • CONCLUSIONS: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients.
  • The inverse correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to understanding the clinical and biological relevance of miR-92a in acute leukemia.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] Nat Immunol. 2008 Aug;9(8):839-45 [18645592.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5473-7 [19706812.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4169-78 [19749093.001]
  • [Cites] PLoS One. 2009;4(11):e7826 [19915715.001]
  • [Cites] Sci Signal. 2009 Dec 8;2(100):ra81 [19996457.001]
  • [Cites] J Biol Chem. 2010 Jun 4;285(23):17442-52 [20353945.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):743-8 [19672257.001]
  • [Cites] Br J Haematol. 2008 May;141(5):672-5 [18318758.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1147-54 [18429962.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):856-64 [18688024.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • [Cites] Cancer Sci. 2009 May;100(5):970-7 [19298223.001]
  • [Cites] PLoS One. 2009;4(5):e5532 [19440243.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):551-6 [19638982.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jan;25(1):1-10 [15684617.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W339-44 [17553836.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1217-23 [19195700.001]
  • (PMID = 21182798.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022817
  •  go-up   go-down


43. Goyal M, Mohammad N, Palanki SD, Vaniawala SN: Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature. Indian J Med Paediatr Oncol; 2010 Jul;31(3):96-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature.
  • Primary plasma cell leukemia is a rare form of plasma cell dyscrasia.
  • We present a case which had leukocytosis with numerous circulating plasma cells in the peripheral blood.
  • The patient was given chemotherapy and was subjected to autologous stem cell transplant, after which she is in complete remission till date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):88-90 [1511063.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):5-6 [17325841.001]
  • [Cites] Eur J Haematol Suppl. 1989;51:76-83 [2697596.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):905-12 [6401225.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1179-84 [17908524.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1343-53 [18509355.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):25-30 [8907265.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1269-73 [8343266.001]
  • (PMID = 21206718.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3009444
  • [Keywords] NOTNLM ; Flow cytometry / fluorescent in-situ hybridization / free light chains / primary plasma cell leukemia / transplant
  •  go-up   go-down


44. Martín P, Santón A, García-Cosío M, Bellas C: RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies. Int J Oncol; 2005 Oct;27(4):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal gammopathies are a group of diseases characterised by the proliferation of a single clone of plasma cells that produce a homogeneous monoclonal protein (M protein or myeloma protein) that consist of two heavy polypeptide chains of the same class and subclass and two light polypeptide chains of the same type.
  • In this study, we have analysed K-ras codon 12 and N-ras codon 61 mutations on anti-CD138 sorted bone marrow plasma cell samples of 44 cases of monoclonal gammopathies: 30 MM, 13 MGUS and 1 plasma cell leukaemia, using polymerase chain reaction.
  • [MeSH-minor] Alleles. Bone Marrow / metabolism. Bone Marrow Cells / cytology. Codon. DNA Primers / chemistry. Female. Humans. Membrane Glycoproteins / biosynthesis. Myeloma Proteins / metabolism. Peptides / chemistry. Point Mutation. Polymerase Chain Reaction. Proteoglycans / biosynthesis. Sensitivity and Specificity. Sequence Analysis, DNA. Spain. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142319.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / Myeloma Proteins; 0 / Peptides; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 0 / multiple myeloma M-proteins
  •  go-up   go-down


45. Longo MS, Carone DM, NISC Comparative Sequencing Program, Green ED, O'Neill MJ, O'Neill RJ: Distinct retroelement classes define evolutionary breakpoints demarcating sites of evolutionary novelty. BMC Genomics; 2009;10:334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the orthologous human EB (14q32.33), known to be associated with translocations in many cancers including multiple myelomas and plasma cell leukemias, and found a conserved distribution of similar repetitive elements.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):115-8 [15305065.001]
  • [Cites] J Virol. 2004 Aug;78(16):8788-98 [15280487.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1851-60 [15364903.001]
  • [Cites] Nucleic Acids Res. 1982 Dec 20;10(24):8155-70 [6819544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Feb;81(3):814-8 [6583681.001]
  • [Cites] Cytogenet Cell Genet. 1996;73(1-2):123-9 [8646879.001]
  • [Cites] Blood. 1997 Jul 15;90(2):526-34 [9226151.001]
  • [Cites] J Virol. 1998 Mar;72(3):1870-5 [9499038.001]
  • [Cites] Mol Biol Evol. 1998 May;15(5):611-2 [9580992.001]
  • [Cites] Nature. 1998 May 7;393(6680):68-72 [9590690.001]
  • [Cites] Leuk Lymphoma. 1998 May;29(5-6):563-75 [9643570.001]
  • [Cites] Genome Res. 2004 Nov;14(11):2235-44 [15479945.001]
  • [Cites] J Virol. 2005 Jan;79(1):341-52 [15596828.001]
  • [Cites] Hum Mutat. 2005 Jan;25(1):45-55 [15580561.001]
  • [Cites] Genome Res. 2005 Jan;15(1):98-110 [15590940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3354-9 [15718282.001]
  • [Cites] J Hered. 2005 May-Jun;96(3):217-24 [15653556.001]
  • [Cites] Science. 2005 Jul 22;309(5734):613-7 [16040707.001]
  • [Cites] Trends Genet. 2006 Jun;22(6):297-301 [16678302.001]
  • [Cites] BMC Bioinformatics. 2006;7:474 [17064419.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:407-42 [16780417.001]
  • [Cites] Genome Biol. 2006;7(12):R115 [17156441.001]
  • [Cites] Mutat Res. 2007 Mar 1;616(1-2):46-59 [17157332.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):507-12 [17392779.001]
  • [Cites] Genetics. 2007 Dec;177(4):2507-17 [18073443.001]
  • [Cites] Genome Biol. 2007;8(8):R170 [17708770.001]
  • [Cites] Genome Res. 2008 Mar;18(3):370-9 [18230801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11845-50 [18701715.001]
  • [Cites] Chromosoma. 2009 Feb;118(1):113-25 [18839199.001]
  • [Cites] Genome Res. 2009 Feb;19(2):178-90 [19029537.001]
  • [Cites] Chromosome Res. 1999;7(6):461-74 [10560969.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):349-63 [11241788.001]
  • [Cites] Mamm Genome. 2001 Mar;12(3):256-9 [11252178.001]
  • [Cites] Chromosome Res. 2001;9(4):301-8 [11419794.001]
  • [Cites] J Mol Evol. 2001 Sep;53(3):237-43 [11523010.001]
  • [Cites] Genomics. 2002 Sep;80(3):331-43 [12213204.001]
  • [Cites] Genome Res. 2003 Jan;13(1):37-45 [12529304.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):601-7 [12508121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7672-7 [12810957.001]
  • [Cites] Cytogenet Genome Res. 2003;102(1-4):282-90 [14970718.001]
  • [Cites] Genome Res. 2004 Apr;14(4):507-16 [15059991.001]
  • [Cites] J Hered. 2004 Sep-Oct;95(5):375-81 [15388765.001]
  • (PMID = 19630942.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Euchromatin
  • [Other-IDs] NLM/ PMC2736999
  •  go-up   go-down


46. Martín-Ayuso M, Almeida J, Pérez-Andrés M, Cuello R, Galende J, González-Fraile MI, Martín-Nuñez G, Ortega F, Rodríguez MJ, San Miguel JF, Orfao A: Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist; 2008 Jan;13(1):82-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.
  • Objectives. The information currently available about dendritic cells (DCs) in patients with different types of monoclonal gammopathy (MG) is limited and frequently controversial.
  • Methods. For this purpose, 61 untreated patients in total with MG were analyzed-MG of undetermined significance (MGUS), 29 cases; multiple myeloma (MM), 28 cases; and plasma cell leukemia (PCL), 4 cases-in comparison with a group of 10 healthy controls.
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Dendritic Cells / pathology. Female. Humans. Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / physiopathology. Male. Middle Aged. Multiple Myeloma / blood. Multiple Myeloma / physiopathology. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245015.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Jost E, Gezer D, Wilop S, Suzuki H, Herman JG, Osieka R, Galm O: Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett; 2009 Aug 18;281(1):24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analysed the clinical impact of epigenetic dysregulation of the Wnt pathway in malignant plasma cell disorders.
  • In multiple myeloma (MM) cell lines, aberrant promoter hypermethylation of the secreted Frizzled-related protein (SFRP) genes was a common event, and hypermethylation of SFRP1,-2 and -5 was associated with transcriptional silencing.
  • Hypermethylation of SFRP1 and -2 genes was detected in monoclonal gammopathy of undetermined significance and all MM stages including plasma cell leukaemia (PCL), while SFRP5 methylation was restricted to advanced MM stages and PCL.
  • Our data indicate that epigenetic silencing of Wnt antagonists is an early event in MM pathogenesis and that SFRP5 hypermethylation may play a role in disease progression.
  • [MeSH-major] CpG Islands. DNA Methylation. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Eye Proteins / genetics. Intercellular Signaling Peptides and Proteins / genetics. Leukemia, Plasma Cell / genetics. Membrane Proteins / genetics. Multiple Myeloma / genetics. Neoplasm Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Female. Humans. Infant, Newborn. Male. Middle Aged. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfites / pharmacology. Survival Analysis. Wnt Proteins / physiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. SODIUM BISULFITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299079.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP1 protein, human; 0 / SFRP2 protein, human; 0 / SFRP4 protein, human; 0 / SFRP5 protein, human; 0 / Sulfites; 0 / Wnt Proteins; TZX5469Z6I / sodium bisulfite
  •  go-up   go-down


48. Singh T, Premalata C, Sajeevan K, Jain A, Batra U, Saini K, Satheesh C, Babu KG, Lokanatha D: IgA plasma cell leukemia. J Lab Physicians; 2009 Jan;1(1):19-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgA plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare entity.
  • The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase.
  • The PCL is a rare disorder representing 1-2% of the diagnosed cases of MM.
  • There was poor response and patient died three months after diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Blood. 1990 Jul 15;76(2):377-82 [1695113.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):901-4 [9404934.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • (PMID = 21938244.001).
  • [ISSN] 0974-2727
  • [Journal-full-title] Journal of laboratory physicians
  • [ISO-abbreviation] J Lab Physicians
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167960
  • [Keywords] NOTNLM ; Primary plasma cell leukemia / multiple myeloma / plasma cell dyscrasia
  •  go-up   go-down


49. Petrucci MT, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P, Torromeo C, Foà R: Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma; 2007 Jan;48(1):180-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Leukemia, Plasma Cell / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inhibitors / adverse effects. Angiogenesis Inhibitors / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / drug therapy. Multiple Myeloma / mortality. Prognosis. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jan;48(1):5-6 [17325841.001]
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1423-5 [17613775.001]
  • (PMID = 17325863.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


50. Usha, Agarwal N, Kumar P, Rai M, Singh RG, Seth M, Saraf SK: Myeloma in young age. Indian J Pathol Microbiol; 2005 Jul;48(3):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One case presented with bleeding gum, malena and hepatosplenomegaly and was diagnosed as plasma cell leukemia.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761740.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Immunoglobulin G; 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


51. Karpas A, Harder L, Czepulkowski B, Bloxham D, Saward R, Dremucheva A, Siebert R: Studies of four new human myeloma cell lines. Leuk Lymphoma; 2005 Jan;46(1):101-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of four new human myeloma cell lines.
  • We describe the establishment and studies of four myeloma cell lines that were derived from 2 young individuals with plasma cell leukaemia (Karpas 25 and 1272) and from 2 older persons with multiple myeloma (Karpas 417 and 929).
  • The cultured cells have the ultrastructural appearance of plasma cells with abundant rough endoplasmic reticulum (RER).
  • Their phenotypic profile conform with that of malignant plasma cells.
  • Karyotype analysis revealed that each cell line is unique and all are hyperdipoide with complex aberrant chromosomes.
  • FISH analysis revealed cryptic translocations affecting the IGH locus in 14q32 of 2 of these cell lines.
  • Using R- and G-banding numerous other chromosomal abnormalities were recorded and illustrated in each of the 4 cell lines.
  • [MeSH-major] Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / pathology
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosomes, Human / genetics. Endoplasmic Reticulum / ultrastructure. Humans. Immunoglobulins / immunology. Immunoglobulins / metabolism. Karyotyping. Microscopy, Electron. Phenotype

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621787.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


52. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J, Stebbins JL, Zhai D, Sun J, Yang L, Dahl R, Zhang Z, Wu B, Wang S, Reed TA, Wang HG, Lawrence N, Sebti S, Reed JC, Pellecchia M: Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther; 2009 Apr;8(4):904-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each compound was subsequently tested for its ability to inhibit Bcl-XL in an in vitro fluorescence polarization competition assay and exert single-agent proapoptotic activity in human cancer cell lines.
  • The most potent compound BI79D10 binds to Bcl-XL, Bcl-2, and Mcl-1 with IC50 values of 190, 360, and 520 nmol/L, respectively, and potently inhibits cell growth in the H460 human lung cancer cell line with an EC50 value of 680 nmol/L, expressing high levels of Bcl-2.
  • BI79D10 also effectively induces apoptosis of the RS11846 human lymphoma cell line in a dose-dependent manner and shows little cytotoxicity against bax-/-bak-/- mouse embryonic fibroblast cells, in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that BI79D10 has little off-target effects.
  • BI79D10 displays in vivo efficacy in transgenic mice, in which Bcl-2 is overexpressed in splenic B cells.
  • Together with its improved plasma and microsomal stability relative to Apogossypol, BI79D10 represents a lead compound for the development of novel apoptosis-based therapies for cancer.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Jul;8(1):5-6 [16023593.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):970-81 [16909112.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Mol Cancer Ther. 2008 Jun;7(6):1639-46 [18566235.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):107-13 [18782651.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] Anticancer Drugs. 2000 Mar;11(3):209-16 [10831280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):173-82 [11175750.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nat Rev Drug Discov. 2002 Feb;1(2):111-21 [12120092.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Adv Pharmacol. 1997;41:501-32 [9204157.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):3-13 [9685174.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [ErratumIn] Mol Cancer Ther. 2009 Jul 1;8(7):2076. Wang, Hong-Gang [added]
  • (PMID = 19372563.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113318-04; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / CA113318; United States / NCI NIH HHS / CA / U19 CA113318-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bak1 protein, mouse; 0 / Bax protein (53-86); 0 / Bax protein, mouse; 0 / Bcl-2-like protein 11; 0 / Mcl1 protein, mouse; 0 / Membrane Proteins; 0 / Membranes, Artificial; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypol; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS107825; NLM/ PMC2750823
  •  go-up   go-down


53. Castellano-Sanchez AA, Kreisel FH: Pathologic quiz case: a 39-year-old man with severe lower back pain. Plasma cell leukemia. Arch Pathol Lab Med; 2005 Mar;129(3):e70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: a 39-year-old man with severe lower back pain. Plasma cell leukemia.
  • [MeSH-major] Leukemia, Plasma Cell / complications. Low Back Pain / etiology. Pain, Intractable / etiology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737053.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF: Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol; 2008 Apr;141(2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
  • ZHX2 was weakly expressed in high-risk/proliferative disease compared to low-risk or indolent disease.
  • RCBTB2 expression was weaker in hyperdiploid versus non-hyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / metabolism. Female. Gene Expression. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / metabolism. Plasma Cells / metabolism. Prognosis. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. ran GTP-Binding Protein / genetics. ran GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353163.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / RAN protein, human; 0 / RCBTB2 protein, human; 0 / Transcription Factors; 0 / ZHX2 protein, human; EC 3.6.5.2 / ran GTP-Binding Protein
  •  go-up   go-down


55. Tageja N, Nagi J, Valent J, Zonder J: Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy. South Med J; 2010 Jul;103(7):706-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.
  • A case of steroid-refractory organizing pneumonia (OP) as the initial presentation of plasma cell leukemia (PCL) in a patient who had no prior exposure to chemotherapy or radiation is described.
  • Since OP is traditionally a steroid-responsive disease, this case raises the possibility of a previously unknown patient subgroup with variable disease pattern and/or behavior in patients with plasma cell neoplasm.
  • [MeSH-major] Cryptogenic Organizing Pneumonia / diagnosis. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Glucocorticoids / therapeutic use. Humans. Lung / pathology. Middle Aged. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531051.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


56. Cunha BA, Bouyarden M, Hamid NS: Fever of unknown origin (FUO) caused by multiple myeloma: the diagnostic value of the Naprosyn test. Heart Lung; 2006 Sep-Oct;35(5):358-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hematologic malignancies, that is, the acute and chronic leukemias, myeloproliferative disorders, and multiple myeloma, do not usually present with acute fevers or as FUOs.
  • Differential diagnostic possibilities in this patient included plasma cell leukemia, relapse of multiple myeloma, secondary/superimposed malignancy, or opportunistic infection.
  • The main differential diagnosis for his FUO was between neoplastic and infectious disorders.
  • The Naprosyn test was positive, which indicated a neoplastic explanation for the patient's FUO and eliminated, along with the infectious disease workup, an infectious explanation for his FUO.
  • The patient's FUO was finally determined to be the result of a relapse of multiple myeloma and not of a secondary malignancy or malignant transformation of myeloma into plasma cell leukemia.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. NAPROXEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963369.001).
  • [ISSN] 0147-9563
  • [Journal-full-title] Heart & lung : the journal of critical care
  • [ISO-abbreviation] Heart Lung
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 57Y76R9ATQ / Naproxen
  •  go-up   go-down


57. Xu W, Li JY, Fan L, Chen LJ, Qiu HR, Wang R, Qiao C, Lu H: [Detection of chromosome 13 deletion in plasma cell leukemia by dual-color fluorescence in situ hybridization]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of chromosome 13 deletion in plasma cell leukemia by dual-color fluorescence in situ hybridization].
  • This study was aimed to investigate the deletion features of chromosome 13 in plasma cell leukemia (PCL) and its relationship with clinical features.
  • The number of 13q14 deletion cells ranged from 52% to 98%.
  • The number of cells with 13q31 deletion ranged from 50% to 98%.

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099623.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


58. Kouno T, Watanabe T, Umeda T, Beppu Y, Kojima R, Sungwon K, Kobayashi Y, Tobinai K, Hasegawa T, Matsuno Y: CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. Jpn J Clin Oncol; 2005 Feb;35(2):90-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora.
  • Monoclonal gammopathy of undetermined significance does not overexpress cluster of differentiation (CD) 56, but plasma cell myeloma frequently overexpressed it.
  • However, plasma cell leukemia and extramedullary plasmacytoma usually down-regulate CD56 expression.
  • Plasmacytoma, especially 'solitary plasmacytoma of bone', is difficult to diagnose as plasma cell neoplasm, because it occasionally appears similar to other bone tumors, both clinically and pathologically, and is rarely accompanied by monoclonal protein in the serum or urine.
  • The present case was a patient with an osteolytic 'small round cell tumor' of the iliac bone, which also invaded the femora.
  • An immunohistopathological finding of CD56 expression played a key role in making a diagnosis.
  • The definitive diagnosis of plasmacytoma was made based on the electron microscopic findings.
  • The plasma cells which infiltrated her sternum showed the same restriction to kappa light chain expression in their cytoplasms as that of the iliac bone tumor cells, but did not express CD56.
  • [MeSH-major] Antigens, CD56 / biosynthesis. Bone Neoplasms / diagnosis. Plasmacytoma / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709094.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


59. Khosravi Shahi P: [Plasma cell leukaemia: a rare variant of multiple myeloma. A case report]. An Med Interna; 2005 Nov;22(11):532-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukaemia: a rare variant of multiple myeloma. A case report].
  • [Transliterated title] Leucemia de células plasmáticas: variante rara del mieloma múltiple. Caso clínico.
  • Plasma cell leukaemia is a rare variant of multiple myeloma (2-3%), with an aggressive disease with short survival.
  • It is defined as circulating peripheral blood plasma cells exceeding 2.000/ul and 20% of peripheral blood white cells.
  • We present the case of 32-years-old man with left chest-wall pain, hepatomegaly, righ cervical adenopathy, 8800 leukocytes/ul with 33% of lymphocytes and 40% of plasma cell, 10.8 g/dl of proteins and a monoclonal hypergammaglobulinemia.
  • Bone marrow biopsy showed 40-50 % of intramedullary plasma cell.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454587.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Ota T, Tsuji Y, Kawasaki R, Taniguchi T, Morimoto Y, Okita Y: Endovascular treatment of aortoureteric fistula. J Endovasc Ther; 2005 Jun;12(3):411-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He died of coexistent plasma cell leukemia 42 days after the operation; however, complete hemostasis had been maintained, and infection around the stent-graft was not recognized at autopsy.

  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943520.001).
  • [ISSN] 1526-6028
  • [Journal-full-title] Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
  • [ISO-abbreviation] J. Endovasc. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Majumdar N, Kumar R, Anand M, Kalita D, Ghara N, Chopra A, Medhi K, Sharma A, Kumar L, Raina V: Plasma cell leukemia--a study of 28 cases from India. Hematology; 2009 Aug;14(4):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia--a study of 28 cases from India.
  • Plasma cell leukemia (PCL) is a rare neoplasm that has not been comprehensively reported in an Indian population.
  • Misdiagnosis as acute leukemia or the leukemic phase of lymphoma on the initial peripheral blood smear examination was frequent (31.4% cases) in the primary form of PCL.
  • Response to treatment is poor and PCL has a poor prognosis, a situation that may be amenable to improvement by a better understanding of the biology of the disease.
  • [MeSH-major] Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635182.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Martin P, Santón A, García-Cosio M, Bellas C: hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol; 2006 Jul;19(7):914-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal gammopathies are a group of disorders characterized by clonal proliferation and accumulation of immunoglobulin-producing plasma cells.
  • Multiple myeloma and monoclonal gammopathy of undetermined significance are the most common monoclonal gammopathies; the two comprise a spectrum of disorders, ranging from a relatively benign disease, monoclonal gammopathy of undetermined significance, to a malignant disease, multiple myeloma.
  • With the purpose of studying the gene silencing of MGMT and hMLH1 in plasma cell disorders, we investigated the methylation status and expression of both genes in: 29 cases of multiple myeloma; one case of plasma cell leukaemia; 13 cases of monoclonal gammopathy of undetermined significance; and two cases of polyclonal plasmacytosis, using methylation-specific polymerase-chain reaction and immunohistochemical techniques.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607377.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


63. Grassinger J, Südhoff T, Andreesen R, Hennemann B: Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol; 2006 Feb;85(2):132-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use. Remission Induction
  • [MeSH-minor] Bortezomib. Hematopoietic Stem Cell Mobilization. Humans. Immunophenotyping. Treatment Outcome

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311736.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


64. Liedtke M, Medeiros BC: Plasma cell leukemia: concepts and management. Expert Rev Hematol; 2010 Oct;3(5):543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: concepts and management.
  • Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia.
  • PCL can present de novo or following a prodrome of plasma cell myeloma.
  • Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers, such as lack of CD56 and presence of CD20.
  • The impact of newer agents, such as bortezomib and lenalidomide, in conjunction with autologous and allogeneic stem cell transplantation is uncertain, but emerging data suggest that use of these modalities may help improve the poor prognosis of patients with PCL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Leukemia, Plasma Cell / therapy. Paraproteinemias / therapy. Pyrazines / administration & dosage. Thalidomide / analogs & derivatives
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antigens, CD56 / analysis. Bortezomib. Humans. Multiple Myeloma / mortality. Multiple Myeloma / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / physiopathology. Neoplasms, Second Primary / therapy. Palliative Care. Prognosis. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083471.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  •  go-up   go-down


65. Sharma A, Kaushal M, Chaturvedi NK, Yadav R: Cytodiagnosis of multiple myeloma presenting as orbital involvement: a case report. Cytojournal; 2006;3:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Plasma cell neoplasms represent autonomous proliferations of plasma cells and can manifest as diffuse myeloma with systemic involvement (plasma cell myeloma or multiple myeloma), monoclonal gammopathy of undetermined significance (MGUS), or as variants of plasma cell myeloma such as indolent myeloma, smoldering myeloma, osteosclerotic myeloma, plasma cell leukaemia and non-secretory myeloma.
  • Localized neoplastic proliferation of plasma cells presents as solitary plasmacytoma of bone or extramedullary plasmacytoma.
  • Early cytological diagnosis of such lesions is vital for timely institution of appropriate therapy.
  • As far as we are aware only six previous cases of cytological diagnosis of multiple myeloma involving the orbit are on record.
  • A fine needle aspirate from the temporal region swelling showed features of a plasmacytoma, and subsequent workup confirmed the presence of systemic disease.
  • A final diagnosis of multiple myeloma with orbital involvement at presentation was made.
  • Fine needle aspiration diagnosis of plasmacytoma at extramedullary sites offers an opportunity for non-invasive verification of systemic involvement, and thus plays a major role in early diagnosis and management of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):104-10 [7846996.001]
  • [Cites] Arch Ophthalmol. 1972 Jan;87(1):30-5 [4550269.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] Arch Ophthalmol. 1977 Apr;95(4):642-4 [849187.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):23-7 [11241503.001]
  • [Cites] Tumori. 2005 May-Jun;91(3):270-2 [16206655.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Br J Ophthalmol. 1953 Sep;37(9):543-54 [13081952.001]
  • [Cites] Cancer. 2001 Aug 25;93(4):257-62 [11507699.001]
  • [Cites] Surv Ophthalmol. 1987 Mar-Apr;31(5):343-51 [3603371.001]
  • (PMID = 16901345.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1564147
  •  go-up   go-down


66. Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L: Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet; 2009 Dec;195(2):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
  • The t(11;14)(q13;q32) is a hallmark of mantle cell lymphoma.
  • It has been found less frequently in other lymphoproliferative disorders, such as B-prolymphocytic leukemia, plasma cell leukemia, chronic lymphocytic leukemia, and multiple myeloma.
  • Here, we describe a patient with acute myeloid leukemia (AML), categorized as M5b according to French-American-British classification, in which conventional cytogenetic analysis revealed a karyotype with t(11;14)(q13;q32).
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic


67. Jiménez-Zepeda VH, Domínguez VJ: Plasma cell leukemia: a rare condition. Ann Hematol; 2006 Apr;85(4):263-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: a rare condition.
  • Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by a malignant proliferation of plasma cells in the bone marrow and peripheral blood.
  • Diagnosis of PCL is established based on Kyle's criteria which include an absolute plasma cell number comprising greater than 20% of peripheral blood cells.
  • PCL has two variants: the primary form presents de novo in patients with no previous history of multiple myeloma (MM) and the secondary form consists of a leukemic transformation in a previously recognized MM.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416115.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin
  •  go-up   go-down


68. Fianchi L, Montini L, Caira M, Voso MT, Maviglia R, Posteraro B, Pagano L: Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. Infection; 2008 Feb;36(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient.
  • Infections by Geotrichum capitatum, occurring in leukemia patients, are rarely reported and generally are characterized by a poor prognosis.
  • Here we reported a case of G. capitatum pneumonia in a patient with plasma cell leukemia, successfully treated with antifungal combination with voriconazole and caspofungin and supportive therapy.
  • [MeSH-minor] Aged. Drug Therapy, Combination. Female. Geotrichum. Humans. Immunocompromised Host. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / drug therapy. Voriconazole

  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926005.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


69. Kim SJ, Kim J, Cho Y, Seo BK, Kim BS: Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol; 2007 May;37(5):382-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
  • Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy.
  • More effective treatment strategies are therefore needed for this disorder.
  • Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide.
  • Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation.
  • Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538191.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


70. Okudaira T, Nagasaki A, Miyagi T, Yoshida M, Tamaki K, Takasu N: [Cauda equina relapse after autologous stem cell transplantation in a patient with primary plasma cell leukemia]. Gan To Kagaku Ryoho; 2010 Apr;37(4):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cauda equina relapse after autologous stem cell transplantation in a patient with primary plasma cell leukemia].
  • We report a rare case showing involvement with the cauda equina after autologous peripheral blood stem cell transplantation for primary plasma cell leukemia (PCL).
  • After achieving hematological remission, he received tandem high-dose melphalan supported by autologous peripheral blood stem cell transplantation.
  • A cytological examination of the cerebrospinal fluid (CSF) with May-Giemsa stain showed atypical plasma cells.
  • A diagnosis of central nervous system (CNS)relapse was made.
  • [MeSH-major] Cauda Equina / pathology. Leukemia, Plasma Cell / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Biopsy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Peripheral Blood Stem Cell Transplantation. Recurrence. Transplantation, Autologous

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414040.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A: Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol; 2010 Aug;150(4):418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukaemia and other aggressive plasma cell malignancies.
  • Extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP) are very aggressive malignancies.
  • These can be primary (de-novo) or secondary due to progressive prior multiple myeloma (MM).
  • Markers of poor prognosis are frequently observed in these extramedullary forms of plasma cell cancers, and survival is significantly inferior compared to patients with MM.
  • Even high dose chemotherapy with autologous stem cell rescue has not been able to demonstrate consistent improvement in survival outcome.
  • Although not specifically evaluated, novel anti-plasma cell agents, such as the proteasome inhibitor bortezomib, and immunomodulatory drugs, such as lenalidomide, appear to be active against these aggressive cancers.
  • Clinical and translational research directed at improved understanding of disease biology and development of novel therapeutics is urgently needed.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Female. Humans. Leukemia, Plasma Cell / diagnosis. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / etiology. Male. Middle Aged. Prognosis. Pyrazines / therapeutic use. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1987 Mar;28(3):428-33 [3613131.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):328-30 [19717386.001]
  • [Cites] Eur J Haematol Suppl. 1989;51:76-83 [2697596.001]
  • [Cites] Rinsho Ketsueki. 1991 Apr;32(4):399-403 [2067085.001]
  • [Cites] Dtsch Med Wochenschr. 1992 Jun 5;117(23):900-4 [1597118.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):1091-5 [8352531.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):262-4 [8296801.001]
  • [Cites] Rinsho Ketsueki. 1994 Aug;35(8):756-60 [7933562.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2398-404 [7964956.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):914-6 [7772534.001]
  • [Cites] Br J Haematol. 1996 May;93(2):345-51 [8639427.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):545-54 [9250826.001]
  • [Cites] Am J Hematol. 1998 Jan;57(1):51-6 [9423817.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):138-43 [10027726.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):28-34 [10444159.001]
  • [Cites] Blood. 1953 Jun;8(6):519-23 [13059037.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Ann Hematol. 2006 Apr;85(4):263-7 [16416115.001]
  • [Cites] Leukemia. 2006 Mar;20(3):542-5 [16408097.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):487-8 [16570151.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1581-3 [16540168.001]
  • [Cites] Haematologica. 2007 Jan;92(1):143-4 [17229655.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1423-5 [17613775.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1426-8 [17613776.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Mar;35(3):533-7 [18347412.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1153-6 [18083228.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):779-84 [18195681.001]
  • [Cites] Leukemia. 2008 May;22(5):1044-52 [18216867.001]
  • [Cites] Med Oncol. 2008;25(2):154-60 [18488157.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1637-8 [18433866.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1249-50 [10586345.001]
  • [Cites] Lancet. 2000 Jan 22;355(9200):248-50 [10675068.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):119-23 [11907796.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):351-4 [11999568.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):882-5 [12060125.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):362-7 [12185504.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17(11):1921-5 [12412796.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):379-80 [12688365.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1026-7 [12873179.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):139-41 [14968586.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):735-8 [15160948.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):821-4 [15160964.001]
  • [Cites] Can Med Assoc J. 1977 Oct 8;117(7):788-9 [907952.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Cancer Causes Control. 2008 Oct;19(8):841-58 [18365759.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):259-62 [18676019.001]
  • [Cites] Acta Haematol. 2009;121(1):47-51 [19339770.001]
  • [Cites] Int J Lab Hematol. 2009 Jun;31(3):338-43 [18284415.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1137-40 [19250676.001]
  • [Cites] Ann Oncol. 2010 Feb;21(2):325-30 [19633044.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • (PMID = 20701603.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121044
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 69
  • [Other-IDs] NLM/ NIHMS585047; NLM/ PMC4044724
  •  go-up   go-down


72. O'Connell TX, Horita TJ, Kasravi B: Understanding and interpreting serum protein electrophoresis. Am Fam Physician; 2005 Jan 1;71(1):105-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma protein levels display reasonably predictable changes in response to acute inflammation, malignancy, trauma, necrosis, infarction, burns, and chemical injury.
  • Monoclonal gammopathies are associated with a clonal process that is malignant or potentially malignant, including multiple myeloma, Waldenstrom's macroglobulinemia, solitary plasmacytoma, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, plasma cell leukemia, heavy chain disease, and amyloidosis.
  • [MeSH-major] Blood Protein Disorders / diagnosis. Blood Protein Electrophoresis / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663032.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


73. Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A, Spanish Network on Multiple Myeloma, Spanish Network of Cancer Research Centers: Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer; 2006 Mar 15;106(6):1296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
  • BACKGROUND: The majority of studies published to date regarding the role of the bone marrow (BM) microenvironment in the pathogenesis of monoclonal gammopathies (MG) have focused on the interaction between stroma cells and plasma cells, whereas information concerning the lymphocytes infiltrating the tumor microenvironment is scanty.
  • METHODS: The authors measured the distribution, TCR-Vbeta repertoire, immunophenotype, and functional characteristics of different subsets of BM T lymphocytes from 61 nontreated patients with MG (30 patients with MG of undetermined significance [MGUS], 27 patients with multiple myeloma [MM], and 4 patients with plasma cell leukemia [PCL]).
  • RESULTS: The authors found a significantly increased rate of BM infiltration by T cells in all patient groups, at the expense of CD4+CD8- and CD4-CD8- T lymphocytes and both CD4+CD28- and CD8+CD28- cytotoxic/effector T cell subsets, and associated with TCR-Vbeta expansions in both CD4+ and CD8+ BM T cells in the majority of patients with MGUS, MM, and PCL.
  • Moreover, the percentage of T cells secreting interferon (IFN)-gamma was found to be increased (P < or = 0.05) both in CD4+ and CD8+ T cells in MGUS and MM patients, and a higher plasma concentration of IFN-gamma was found in patients with MM.
  • It is interesting to note that a positive correlation was noted between the proportion of CD28- and both the percentage of IFN-gamma-secreting cells and the proportion of expanded TCR-Vbeta lymphocytes within the total BM CD4+ T cells.
  • CONCLUSIONS: The results of the current study demonstrated an increased infiltration of BM by T cells associated with frequent TCR-Vbeta expansions and a more prominent cytotoxic/Th1 phenotype in all the patient groups studied.
  • [MeSH-major] Leukemia, Plasma Cell / immunology. Multiple Myeloma / immunology. Paraproteinemias / immunology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. T-Lymphocytes, Cytotoxic / immunology. Th1 Cells / immunology
  • [MeSH-minor] Aged. Antigens, CD / analysis. Bone Marrow Cells / immunology. Case-Control Studies. Female. Humans. Immunophenotyping. Interferon-gamma / secretion. Lymphocyte Count. Lymphocytes, Tumor-Infiltrating / immunology. Lymphocytes, Tumor-Infiltrating / metabolism. Lymphocytes, Tumor-Infiltrating / pathology. Male

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16475149.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, alpha-beta; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


74. Nolan KD, Mone MC, Nelson EW: Plasma cell neoplasms. Review of disease progression and report of a new variant. Surg Oncol; 2005 Aug;14(2):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell neoplasms. Review of disease progression and report of a new variant.
  • Plasma cell neoplasms are generally categorized into four groups; multiple myeloma (MM), solitary plasmacytoma of the bone (SPB), plasma cell leukemias, and extramedullary plasmacytomas (EMP).
  • A plasmacytoma is defined as any discrete, usually solitary mass of neoplastic plasma cells, either in the bone marrow or in various soft tissue sites.
  • Each manifestation of a plasma cell neoplasm differs in terms of tumor recurrence and progression to MM.
  • This pattern of tumor recurrence is unique and the management of gastric plasmacytoma as part of this complex disease is discussed.
  • The continuum of progression between various sites and manifestations of plasma cell manifestations is reviewed including a previously undiscovered sequence of bone disease, gastric disease, and finally multiple myeloma.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Disease Progression. Gastrectomy. Humans. Male. Orthopedic Procedures. Radiotherapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993050.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


75. Thuillier D, Lenglet A, Chaby G, Royer R, Vaida I, Viseux V, Dadban A, Billet A, Christophe O, Chatelain D, Marolleau JP, Lok C, Damaj G: [Bortezomib-induced eruption: Sweet syndrome? Two case reports]. Ann Dermatol Venereol; 2009 May;136(5):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Toxidermie au bortézomib : syndrome de Sweet? Deux cas.
  • PATIENTS AND METHODS: Case 1: bortezomib treatment was started in a 62-year-old man for mantle cell lymphoma.
  • Case 2: a 46-year-old woman was receiving bortezomib treatment for plasma cell leukemia.
  • [MeSH-minor] Biopsy. Bortezomib. Colchicine / therapeutic use. Dexamethasone / therapeutic use. Female. Humans. Leukemia, Plasma Cell / etiology. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Skin Ulcer / chemically induced. Skin Ulcer / pathology. Treatment Outcome

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442799.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; SML2Y3J35T / Colchicine
  •  go-up   go-down


76. Jimenez-Zepeda VH, Dominguez-Martinez VJ: Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol; 2009 Apr;89(3):259-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
  • Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma and is characterized by the presence of >20% and/or an absolute number of greater 2 x 10(9)/L plasma cells circulating in the peripheral blood.
  • PCL represents approximately 2-4% of all MM diagnosis and exists in two forms: primary PCL (PPCL, 60% of cases) presents de novo, whereas secondary PCL (SPCL, accounts for the remaining 40%) consists of a leukemic transformation in patients with a previously diagnosed MM.
  • Because the mechanisms contributing to the pathogenesis of PCL are not fully understood, immunophenotyping, genetic evaluation (conventional karyotype, FISH, GEP and array-CGH), and immunohistochemistry are really important tools to investigate why plasma cells escape from bone marrow and become highly aggressive.
  • [MeSH-major] Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / pathology. Paraproteinemias / complications. Paraproteinemias / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):81-8 [8611480.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3719-36 [12202673.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] PLoS Med. 2007 Mar;4(3):e90 [17388661.001]
  • [Cites] Blood. 1978 Oct;52(4):839-45 [687831.001]
  • [Cites] EMBO J. 1998 Sep 1;17 (17 ):5001-14 [9724636.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Indian J Cancer. 2003 Jul-Sep;40(3):116-7 [14716116.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2271-2 [17107895.001]
  • [Cites] Leukemia. 1999 Dec;13(12 ):2099-103 [10602435.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 1;148(1):71-6 [14697644.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1047-53 [16901028.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):351-4 [11999568.001]
  • [Cites] Curr Treat Options Oncol. 2001 Jun;2(3):205-16 [12057120.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):996-7 [12060146.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):191-200 [18752593.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):259-62 [18676019.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):150-3 [15642395.001]
  • [Cites] Thromb J. 2006 Aug 21;4:11 [16923190.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):486-92 [16978238.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Hum Mutat. 2001 Sep;18(3):212-24 [11524732.001]
  • [Cites] Ann Hematol. 2006 Apr;85(4):263-7 [16416115.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):239-44 [16856924.001]
  • [Cites] Jpn J Clin Oncol. 2007 May;37(5):382-4 [17538191.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17 ):2750-61 [11965548.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4525-30 [12036884.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1153-6 [18083228.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4990-5 [11309512.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):285-9 [16321859.001]
  • [Cites] Br J Haematol. 1991 Feb;77(2):185-90 [1706197.001]
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(9):793-6 [16113669.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4569-75 [12576322.001]
  • [Cites] South Med J. 2009 Jan;102(1):101-3 [19077786.001]
  • [Cites] Eur J Haematol. 1995 May;54(5):334-5 [7781758.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3489-95 [17209057.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S207-14 [17877846.001]
  • [Cites] Med Oncol. 2008;25(2):154-60 [18488157.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2276-84 [17105813.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):2012-4 [18720213.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(1):77-84 [15133485.001]
  • [Cites] Leukemia. 2008 May;22(5):1044-52 [18216867.001]
  • [Cites] Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92 [11943931.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):480-92 [18056678.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2247-56 [18769451.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):486-91 [16995883.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2816-21 [11306450.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):66-8 [17675269.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1168-71 [12149193.001]
  • [Cites] Ann Diagn Pathol. 2006 Oct;10(5):263-8 [16979517.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2133-42 [18032763.001]
  • [Cites] Hematol J. 2004;5(4):361-3 [15297854.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):558-66 [15274069.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Am J Hematol. 1992 Feb;39(2):84-9 [1550111.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1343-53 [18509355.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):755-62 [15953001.001]
  • [Cites] Leukemia. 2007 Mar;21(3):582-4 [17215851.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2034-40 [17024118.001]
  • [Cites] Cytometry. 1994 Dec 1;17(4):332-9 [7533074.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8 [16344099.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2173-9 [9815612.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1423-5 [17613775.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Blood. 1990 Apr 15;75(8):1684-90 [2183888.001]
  • [Cites] Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):456-7 [18723997.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2837-40 [15976175.001]
  • [Cites] Am J Hematol. 2006 Dec;81(12):987-8 [16888783.001]
  • [Cites] Leuk Lymphoma. 1998 Dec;32(1-2):129-38 [10037008.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12):969-72 [18055567.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30 [10386948.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1724-32 [16705089.001]
  • [Cites] Leuk Res. 2001 Feb;25(2):103-7 [11166824.001]
  • [Cites] Br J Haematol. 1991 Dec;79(4):655-6 [1772791.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):349-54 [18759764.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2123-32 [18032762.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):362-7 [12185504.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):25-30 [8907265.001]
  • [Cites] Br J Haematol. 2007 Oct;139(1):51-4 [17854306.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1990 Jul;12(4):314-7 [2272272.001]
  • [Cites] Am J Hematol. 1988 Jun;28(2):113-5 [3394712.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85 [18624684.001]
  • (PMID = 19326058.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 102
  •  go-up   go-down


77. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A: Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene; 2005 Apr 7;24(15):2461-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
  • Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked heterogeneity of genetic lesions and clinical course.
  • It may develop from a premalignant condition (monoclonal gammopathy of undetermined significance, MGUS) or progress from intramedullary to extramedullary forms (plasma cell leukemia, PCL).
  • To provide insights into the molecular characterization of plasma cell dyscrasias and to investigate the contribution of specific genetic lesions to the biological and clinical heterogeneity of MM, we analysed the gene expression profiles of plasma cells isolated from seven MGUS, 39 MM and six PCL patients by means of DNA microarrays.
  • Distinct gene expression patterns have been found to be associated with different lesions: the overexpression of CCND2 and genes involved in cell adhesion pathways was observed in cases with deregulated MAF and MAFB, whereas genes upregulated in cases with the t(4;14) showed apoptosis-related functions.
  • The peculiar finding in patients with the t(11;14) was the downregulation of the alpha-subunit of the IL-6 receptor.
  • In addition, we identified a set of cancer germline antigens specifically expressed in a subgroup of MM patients characterized by an aggressive clinical evolution, a finding that could have implications for patient classification and immunotherapy.
  • [MeSH-major] Gene Expression Profiling. Genetic Predisposition to Disease. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / physiopathology. Multiple Myeloma / genetics. Multiple Myeloma / physiopathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735737.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Interleukin-6
  •  go-up   go-down


78. Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, Björkstrand B, Gahrton G, European Group for Blood and Marrow Transplantation and the European Leukemia Net: Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica; 2010 May;95(5):804-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia and autologous stem cell transplantation.
  • BACKGROUND: Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases.
  • The results of conventional therapy are disappointing though autologous stem cell transplantation may improve survival.
  • DESIGN AND METHODS: A retrospective analysis was undertaken of the European Group for Blood and Marrow Transplantation experience of 272 patients with plasma cell leukemia and 20844 with multiple myeloma undergoing first autologous transplantation between 1980 and 2006.
  • RESULTS: There was no difference in type of graft or use of total body irradiation between patients with plasma cell leukemia and multiple myeloma, but the group with plasma cell leukemia was transplanted earlier after diagnosis (6.0 versus 7.7 months, P=0.000).
  • Patients with plasma cell leukemia were more likely to enter complete remission after transplantation but their overall survival (25.7 months, 95% confidence interval 19.5-31.9 months) was inferior to that of patients with multiple myeloma (62.3 months, 95% confidence interval 60.4-64.3 months) (P=0.000), due to the short duration of their post-transplant response and increased non-relapse-related mortality.
  • CONCLUSIONS: This largest study ever reported on plasma cell leukemia suggests that autologous transplantation can improve outcome, although results are markedly inferior to those achieved in patients with multiple myeloma, highlighting the need for novel approaches to this aggressive disorder.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Plasma Cell / mortality. Leukemia, Plasma Cell / surgery. Transplantation Conditioning

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1998 Jul;102(2):495-502 [9695964.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):901-4 [9404934.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(8):823-5 [9827984.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Acta Haematol. 1999;101(4):193-6 [10436300.001]
  • [Cites] Pharmacotherapy. 2005 Dec;25(12):1820-5 [16305302.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3607-9 [10610115.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(5):511-5 [11313685.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):55-8 [12542443.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1198-204 [1715218.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2539-43 [1461658.001]
  • [Cites] Blood. 1993 Jan 1;81(1):128-35 [8417784.001]
  • [Cites] Blood. 1993 May 15;81(10):2708-13 [8490179.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):914-6 [7772534.001]
  • [Cites] Blood. 1995 Jul 15;86(2):685-91 [7605999.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):225-7 [8832022.001]
  • [CommentIn] Haematologica. 2010 May;95(5):705-7 [20442443.001]
  • (PMID = 20442444.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ G0802523
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864387
  •  go-up   go-down


79. Xu X, Broome EH, Rashidi HH, South ST, Dell'aquila ML, Wang HY: CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma. Int J Clin Exp Pathol; 2010;3(8):798-807
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
  • We report a CD20dim- positive T-cell large granular lymphocytic (T-LGL) leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
  • This patient was first diagnosed with T-LGL leukemia with dim CD20 expression, which by itself was a rare entity.
  • He received no treatment for T-LGL leukemia.
  • The patient later developed a hairy cell leukemia, which went into complete clinical remission after one cycle of 2-CdA.
  • Five years later, he was diagnosed with a third malignancy, plasma cell myeloma.
  • Complex cytogenetic aberrancies were present at the time when plasma cell myeloma was diagnosed.
  • [MeSH-major] Antigens, CD20 / metabolism. Leukemia, Hairy Cell / pathology. Leukemia, Large Granular Lymphocytic / metabolism. Leukemia, Large Granular Lymphocytic / pathology. Multiple Myeloma / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Hum Pathol. 2010 Apr;41(4):461-76 [20226962.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1454-9 [12145685.001]
  • [Cites] Schweiz Med Wochenschr. 1980 Oct 11;110(41):1494-8 [6999621.001]
  • [Cites] Acta Haematol. 1984;72(1):57-60 [6433635.001]
  • [Cites] Cytometry. 1993;14(2):196-204 [7679964.001]
  • [Cites] Leukemia. 1993 Jun;7(6):782-8 [8388971.001]
  • [Cites] Am J Hematol. 1993 Nov;44(3):216-7 [8213782.001]
  • [Cites] Blood. 1994 May 15;83(10):2931-8 [8180388.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4):483-9 [7524302.001]
  • [Cites] Haematologica. 1995 Mar-Apr;80(2):146-9 [7543070.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1803-10 [9164188.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):291-4 [9488615.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1160-4 [9694703.001]
  • [Cites] Blood. 1958 Jul;13(7):609-30 [13560561.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):176-81 [17210522.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):215-22 [17284716.001]
  • [Cites] Int J Hematol. 2007 Nov;86(4):348-51 [18055343.001]
  • [Cites] J Cutan Pathol. 2008 Apr;35(4):398-403 [18261116.001]
  • [Cites] Cancer Invest. 2008 Oct;26(8):860-5 [18798068.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4235-46 [18337559.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):420-4 [19046317.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):e13-6 [18995899.001]
  • [Cites] Intern Med. 2009;48(16):1443-7 [19687595.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1043-8 [11697621.001]
  • (PMID = 21151394.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2993231
  • [Keywords] NOTNLM ; CD20 / T-cell large granular lymphocytic leukemia / hairy cell leukemia / plasma cell myeloma
  •  go-up   go-down


80. Patel RT, Caceres A, French AF, McManus PM: Multiple myeloma in 16 cats: a retrospective study. Vet Clin Pathol; 2005 Dec;34(4):341-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion required an antemortem diagnosis of multiple myeloma using 2 of 4 criteria:.
  • 1) >or=20% plasma cells in the bone marrow, or >or=10% if atypical plasma cells;.
  • Alternatively, a postmortem diagnosis was based on the findings of multiple plasma cell neoplasms, with marrow involvement.
  • Plasma cells were markedly immature, atypical, or both in 10 of 12 (83.3%) cats.
  • The disease in 1 of 2 cats with cutaneous tumors progressed to plasmacytic leukemia.
  • CONCLUSIONS: Common findings in feline multiple myeloma include atypical plasma cell morphology, hypocholesterolemia, anemia, bone lesions, and multi-organ involvement.
  • Based on the results of this study, we advocate modifying diagnostic criteria in cats to include consideration of plasma cell morphology and visceral organ infiltration.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270258.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. John S, Feroze M, Supriya NK, Aisabi KA: Plasma cell leukemia with pleomorphic plasma cells--a case report. Indian J Pathol Microbiol; 2006 Jul;49(3):438-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia with pleomorphic plasma cells--a case report.
  • A case of plasma cell leukemia showing mostly pleomorphic plasma cells in the form of convoluted and multilobated nuclei with some having bilobed nuclei and internuclear bridges is being reported for its rarity of occurrence.
  • Patient is in remission 5 months after diagnosis.
  • The significance of recognising such pleomorphic plasma cells is discussed.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Bence Jones Protein / urine. Diagnosis, Differential. Electrophoresis. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2007 Jan;50(1):45
  • (PMID = 17001915.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


82. Young P, Finn BB, Pellegrini D, Bruetman JE, Shanley CM, Tolosa Vilell C, Trimarchi H: [Myelomatous ascites]. An Med Interna; 2008 Feb;25(2):85-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ascitis mielomatosa: reporte de un caso y revisión de la literatura.
  • It is submitted the case of a female patient aged 50 years with IgA-kappa MM, who evolved with cardiac failure (CF), plasma cells leukemia and ascites of mixed cause, because of peritoneal infiltrate of myelomatous cells, hepatic compromise and CF.
  • Our report presents the first case of myelomatous ascites in a patient with plasma cells leukemia.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432366.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 37
  •  go-up   go-down


83. Colak D, Ozyilkan O, Akcali Z, Bilezikci B: Hodgkin's disease in an elderly patient with B-cell chronic lymphocytic leukemia. Indian J Cancer; 2005 Jul-Sep;42(3):158-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in an elderly patient with B-cell chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) is the most common type of leukemia worldwide.
  • It is an indolent disease, almost exclusively of B-cell origin.
  • Transformation to acute lymphoblastic leukemia, plasma cell leukemia, multiple myeloma, or Hodgkin's disease (HD) may also occur.
  • Herein, we report a case of HD in an elderly man with a history of B-cell CLL.
  • [MeSH-major] Hodgkin Disease / pathology. Leukemia, B-Cell / pathology
  • [MeSH-minor] Chronic Disease. Humans. Male. Middle Aged. Prognosis. Risk Assessment. Risk Factors


84. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, Motta V, Bertazzi PA, Baccarelli A, Neri A: Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis; 2009 Aug;30(8):1330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we used a quantitative bisulfite-polymerase chain reaction pyrosequencing method to evaluate the methylation patterns of LINE-1, Alu and SAT-alpha in 23 human myeloma cell lines (HMCLs) and purified bone marrow plasma cells from 53 newly diagnosed MM patients representative of different molecular subtypes, 7 plasma cell leukemias (PCLs) and 11 healthy controls.
  • Our results indicate that global hypomethylation of repetitive elements is significantly associated with tumor progression in MM and may contribute toward a more extensive stratification of the disease.
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation. DNA, Neoplasm / genetics. Leukemia, Plasma Cell / genetics. Multiple Myeloma / genetics. Repetitive Sequences, Nucleic Acid / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alu Elements / genetics. Chromosome Aberrations. CpG Islands. DNA, Satellite / genetics. Female. Humans. Long Interspersed Nucleotide Elements / genetics. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531770.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Satellite; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1
  •  go-up   go-down


85. Shenoy C: Hyperammonaemic encephalopathy in plasma cell leukaemia. Intern Med J; 2007 Nov;37(11):784-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperammonaemic encephalopathy in plasma cell leukaemia.
  • [MeSH-major] Ammonia / blood. Brain Diseases, Metabolic / etiology. Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908093.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 7664-41-7 / Ammonia
  •  go-up   go-down


86. Chattopadhyay A, Nath UK, De R, Singh A, Sanyal S, Chatterjee SK, Chaudhuri U: Primary plasma cell leukemia with initial cutaneous involvement and IgA biclonal gammopathy. Ann Hematol; 2008 Mar;87(3):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia with initial cutaneous involvement and IgA biclonal gammopathy.
  • [MeSH-major] Immunoglobulin A / blood. Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / pathology. Skin Neoplasms / blood. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909800.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


87. Rodriguez C, Pont JC, Gouin-Thibault I, Andrieu AG, Molina T, Le Tourneau A, Le Garff-Tavernier M, Siguret V, Chaibi P: [Plasma cell leukaemia]. Ann Biol Clin (Paris); 2005 Sep-Oct;63(5):535-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukaemia].
  • [Transliterated title] La leucémie à plasmocytes.
  • We report a case of primary plasma cell leukaemia, with an absolute count of plasma cells of 53 Giga/L, diagnosed in a 83-year-old woman.
  • The patient's condition improved, with no circulating plasma cells after 3 weeks of treatment, in response to the combination of thalidomide and dexamethasone administered for 5 days followed by thalidomide alone.
  • The clinical presentation, the morphological, flow cytometric and pathophysiological characteristics of the plasma cell leukaemia and the treatment are summarised in this paper.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Leukemia, Plasma Cell / diagnosis. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230292.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Inflammatory Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


88. Xu W, Li JY, Fan L, Chen LJ, Qiu HR, Qiu HX, Lu H: Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia. Int J Lab Hematol; 2009 Jun;31(3):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare malignant plasma cell disorder.
  • Cytogenetic studies performed on plasma cell disorders are scarce and difficult because of the low proliferation rate of plasma cells (PCs).
  • Among 21 PCL patients, molecular cytogenetic aberrations were found in 18 (81.8%) patients, four (19.0%) patients simultaneously had 13q14 deletion, illegitimate IgH translocation and 1q abnormality.
  • Chromosome 1 abnormality was found in seven (33.3%) patients, one with deletion of 1q, six with at least three copies amplifications of 1q12 (Amp1q12).
  • It was showed that most PCL had chromosomal abnormalities, 14q32 rearrangement, 13q14 deletion and chromosome 1 abnormality are the frequent abnormalities, and over half of the 14q32 rearrangement were t(11;14) or t(4;14).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 14 / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284415.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A: Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer; 2005 Feb;42(2):117-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the expression profiles of the FGFR3/MMSET, CCND1, CCND3, MAF, and MAFB genes, which are involved in t(4;14)(p16.3;q32), t(11;14)(q13;q32), t(6;14)(p21;q32), t(14;16)(q32;q23), and t(14;20)(q32;q12), respectively, in purified plasma cell populations from 39 MMs and six plasma cell leukemias (PCL) by DNA microarray analysis and compared the results with the presence of translocations as assessed by dual-color FISH or RT-PCR.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15543617.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND3 protein, human; 0 / Carrier Proteins; 0 / Cyclin D3; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / MAFB protein, human; 0 / Macrophage-Activating Factors; 0 / MafB Transcription Factor; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Fibroblast Growth Factor; 0 / Repressor Proteins; 0 / Transcription Factors; 136601-57-5 / Cyclin D1; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / WHSC1 protein, human; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


90. Nakaya A, Ogihara T, Awaya N: Plasma cell leukemia presenting with diplopia due to unilateral abducens paralysis and complex chromosomal abnormalities. Intern Med; 2006;45(9):637-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting with diplopia due to unilateral abducens paralysis and complex chromosomal abnormalities.
  • Involvement of cranial nerves is rare in plasma cell leukemia (PCL).
  • Although the patient showed an initial response to chemotherapy, he died of disease progression 5 months later.
  • [MeSH-major] Abducens Nerve Diseases / complications. Chromosome Aberrations. Diplopia / etiology. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / genetics. Paralysis / complications
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Disease Progression. Fatal Outcome. Humans. Liver / radiography. Magnetic Resonance Imaging. Male. Sphenoid Sinus / pathology. Tomography, X-Ray Computed. Translocation, Genetic

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755096.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Oka S, Yokote T, Akioka T, Hara S, Yamano T, Tsuji M, Hanafusa T: Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leuk Res; 2006 Dec;30(12):1581-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia.
  • The laboratory findings showed increased white blood cells at 11.37 x 10(3)cells/microl with 26.5% abnormal cells, low haemoglobin and, elevated creatinine, although serum lactate dehydrogenase and calcium levels were normal.
  • Bone marrow aspiration showed 59.5% infiltration of abnormal cells that were characterized by typical mature plasmacytoid morphology.
  • Abnormal cells expressed surface CD20, surface CD138, and cytoplasmic IgM, but not surface CD56 nor surface IgM by flow cytometric immunophenotyping with CD38 gating.
  • The clinical findings led to the diagnosis of the IgM Plasma cell leukemia (PCL).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Immunoglobulin M / blood. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540168.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin M; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


92. Bow EJ: Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint. Mycopathologia; 2009 Dec;168(6):283-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint.
  • The practice of hematopoietic stem cell transplantation (HSCT) has undergone many changes that affect the likelihood that a given patient would develop an invasive fungal infection (IFI).
  • Important recipient-related factors include age, state of the underlying disease for which the HSCT is being done, and treatment-related history.
  • Transplant procedure-related factors include the type of transplant (autologous or allogeneic), the use of and timing of anti-fungal prevention strategies including whether or not the transplant was conducted in a protected environment to minimize environmental exposure to mould conidia, the choice of conditioning (myeloablative or non-myeloablative), human leucocyte antigen-relatedness [autologous, matched related, mismatched related (including haploidentical pairings), unrelated (matched or mismatched)], stem cell source (bone marrow, peripheral, or cord blood), stem cell dosing, and stem cell product processing (red cell, plasma, or T-lymphocyte depletions, or CD34 selections).
  • Transplant-related complications include duration of pre-engraftment period of neutropenia, graft failure or rejection, the degree of cytotoxic conditioning therapy-related intestinal mucosal damage, acute and chronic graft-versus-host disease (GvHD), the use of corticosteroids for the prevention or management of GvHD, the presence of cytomegalovirus infection and disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Mycoses / epidemiology
  • [MeSH-minor] Antifungal Agents / therapeutic use. Graft vs Host Disease / etiology. Humans. Immunosuppression / adverse effects. Mitosporic Fungi / drug effects. Neutropenia / etiology. Physicians. Risk Factors

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 15;102(2):756-62 [12663454.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):335-47 [17251530.001]
  • [Cites] Br J Haematol. 2002 May;117(2):259-64 [11972507.001]
  • [Cites] J Hosp Infect. 2001 Jul;48(3):198-206 [11439007.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):857-64 [16532017.001]
  • [Cites] MMWR Recomm Rep. 1997 Jan 3;46(RR-1):1-79 [9036304.001]
  • [Cites] Medicine (Baltimore). 2007 Nov;86(6):324-33 [18004177.001]
  • [Cites] MMWR Recomm Rep. 2003 Jun 6;52(RR-10):1-42 [12836624.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Sep;11(9):680-7 [16125638.001]
  • [Cites] Med Mycol. 2006 Jun;44(4):295-327 [16772225.001]
  • [Cites] Clin Microbiol Infect. 2004 Mar;10 Suppl 1:48-66 [14748802.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Apr;43(4):836-45 [10103188.001]
  • [Cites] Ann Hematol. 2000 Nov;79(11):627-30 [11131922.001]
  • [Cites] Mycoses. 2008 Nov;51(6):542-5 [18422921.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Semin Hematol. 1991 Jul;28(3):250-9 [1887253.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Ann Intern Med. 1984 Mar;100(3):345-51 [6696356.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1519-25 [18268357.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14 ):1391-402 [15459300.001]
  • [Cites] Am J Med. 1987 Oct;83(4):709-18 [3314494.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):211-4 [10918433.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):27-33 [10037047.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1122-31 [12715306.001]
  • [Cites] Clin Infect Dis. 2005 Aug 15;41(4):521-6 [16028162.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 May;9(5):292-303 [12766879.001]
  • [Cites] Eur J Haematol. 1999 Aug;63(2):77-85 [10480286.001]
  • [Cites] Pharmacotherapy. 2005 Sep;25(9):1181-92 [16164393.001]
  • [Cites] MMWR Recomm Rep. 2004 Mar 26;53(RR-3):1-36 [15048056.001]
  • [Cites] Cancer. 2008 Jun;112(11):2493-9 [18412153.001]
  • [Cites] Clin Infect Dis. 2003 Jan 1;36(1):9-15 [12491195.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2768-76 [12855583.001]
  • [Cites] Exp Hematol. 1999 Mar;27(3):561-8 [10089920.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jan;9(1):52-9 [12533742.001]
  • [Cites] Support Care Cancer. 2006 Jun;14(6):580-2 [16775651.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(2):143-7 [9116611.001]
  • [Cites] Med Mycol. 2008 Sep;46(6):541-6 [19180749.001]
  • [Cites] Blood. 2004 Aug 15;104(4):961-8 [15113759.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):225-34 [11807146.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):569-72 [11681437.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1545-52 [7769290.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1995 Jun;14(6):552-6 [7588835.001]
  • [Cites] J Infect Dis. 1991 Oct;164(4):731-40 [1894935.001]
  • [Cites] Med Mycol. 2008 Jun;46(4):293-302 [18415836.001]
  • [Cites] Haematologica. 2008 Jan;93(1):104-10 [18166792.001]
  • [Cites] Clin Infect Dis. 2002 Apr 1;34(7):909-17 [11880955.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(7):735-9 [14755318.001]
  • [Cites] Mycopathologia. 2005 Feb;159(2):181-8 [15770441.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):374-7 [12185506.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1069-85 [16757972.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(12):1173-9 [15094754.001]
  • [Cites] Blood. 2003 Aug 1;102(3):827-33 [12689933.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1303-6 [17614303.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):416-23 [14691124.001]
  • [Cites] Support Cancer Ther. 2007 Sep 1;4(4):188-97 [18632516.001]
  • [Cites] Clin Infect Dis. 1999 Feb;28(2):250-5 [10064240.001]
  • [Cites] N Engl J Med. 1992 Mar 26;326(13):845-51 [1542320.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3142-6 [15243073.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2254-61 [9196138.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S27-9 [18545239.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2726-33 [11929759.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):451-7 [9053465.001]
  • [Cites] Transplantation. 2000 Apr 15;69(7):1341-7 [10798751.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):537-46 [10653869.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42(4):275-9 [18500368.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):481-6 [17618322.001]
  • [Cites] Bone Marrow Transplant. 1996 Apr;17(4):555-60 [8722354.001]
  • [Cites] Transpl Infect Dis. 2008 Jun;10(3):162-7 [17662036.001]
  • [Cites] MMWR Recomm Rep. 2000 Oct;49(RR-10):1-125, CE1-7 [11718124.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):783-9 [18541197.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):767-74 [12461585.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2087-92 [17082779.001]
  • [Cites] J Infect Dis. 1986 Mar;153(3):634-7 [2936830.001]
  • [Cites] Haematologica. 1999 Feb;84(2):167-76 [10091416.001]
  • [Cites] Antimicrob Agents Chemother. 2008 May;52(5):1743-50 [18212110.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2614 [15746087.001]
  • [Cites] Transfusion. 1998 Feb;38(2):199-208 [9531955.001]
  • [Cites] J Infect Dis. 2006 May 15;193(10):1408-18 [16619189.001]
  • [Cites] Clin Infect Dis. 2004 May 1;38(9):1237-42 [15127334.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):771-7 [17580255.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3216-22 [16835378.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(8):801-8 [9134172.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Feb;6(2):183-9 [18319050.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Sep;23(9):525-31 [12269451.001]
  • [Cites] Bone Marrow Transplant. 2008 Sep;42(5):337-43 [18560408.001]
  • [Cites] Mycopathologia. 2006 Jul;162(1):1-15 [16830186.001]
  • [Cites] Int J Hematol. 2003 May;77(4):399-407 [12774932.001]
  • [Cites] Clin Infect Dis. 2004 Nov 15;39(10):1407-16 [15546073.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):102-8 [16405430.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):1017-21 [18721764.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(5):281-9 [12064366.001]
  • [Cites] Clin Infect Dis. 2008 Aug 15;47(4):503-9 [18611163.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1550-8 [15150081.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4705-9 [9389685.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(6):663-6 [11041569.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]
  • [Cites] Blood. 2004 Aug 1;104(3):649-54 [15069017.001]
  • [Cites] Br J Haematol. 2000 Aug;110(2):292-9 [10971384.001]
  • [Cites] Eur J Haematol. 2004 Sep;73(3):174-8 [15287914.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(5):525-9 [11313687.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):874-85 [12786798.001]
  • [Cites] Med Mycol. 2005 May;43 Suppl 1:S49-58 [16110792.001]
  • [Cites] J Infect Dis. 1997 Jun;175(6):1459-66 [9180187.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):813-31 [12476273.001]
  • [Cites] Blood. 2005 Jul 1;106(1):27-34 [15761020.001]
  • [Cites] Clin Infect Dis. 2008 Oct 15;47(8):1041-50 [18781877.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):634-53 [16080086.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):119-24 [14508798.001]
  • [Cites] Bone Marrow Transplant. 2007 Nov;40(10):983-8 [17846600.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(7):707-11 [15785771.001]
  • [Cites] Clin Infect Dis. 1999 Feb;28(2):331-40 [10064252.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):348-59 [17251531.001]
  • [Cites] J Clin Microbiol. 2004 Oct;42(10):4419-31 [15472288.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1527-33 [14525770.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2470-5 [18042798.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1161-70 [17918077.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] J Infect Dis. 1995 Oct;172(4):1035-41 [7561177.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):181-94 [18241628.001]
  • [Cites] Clin Infect Dis. 2001 Dec 15;33(12):1959-67 [11702290.001]
  • [Cites] Clin Microbiol Infect. 2002 Jul;8(7):405-12 [12199850.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):512-20 [12374456.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):475-82 [11841455.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2095-7 [14959853.001]
  • (PMID = 19343534.001).
  • [ISSN] 1573-0832
  • [Journal-full-title] Mycopathologia
  • [ISO-abbreviation] Mycopathologia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 131
  •  go-up   go-down


93. Parker H, Cheung KL, Robinson HM, Harrison CJ, Strefford JC: Cytogenetic and genomic characterization of cell line ARH77. Cancer Genet Cytogenet; 2008 Feb;181(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and genomic characterization of cell line ARH77.
  • The cell line ARH77 is derived from a patient with plasma cell leukemia and has a complex and continually evolving karyotype.
  • It is frequently used in biological studies of myeloma and plasma cell leukemia, so accurate characterization of the genome is valuable.
  • Conventional cytogenetics and M-FISH indicated the location and types of the major chromosomal changes, whether balanced or unbalanced, and at the same time demonstrated the level of karyotypic evolution between cells.
  • [MeSH-major] Leukemia, Plasma Cell / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosome Mapping. Gene Expression Profiling. Genome, Human. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Nucleic Acid Hybridization. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262052.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L, Merigiola C, Giordano G, Tabilio A: Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol; 2007 Dec;4(12):722-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
  • BACKGROUND: A 68-year-old man diagnosed with primary plasma-cell leukemia was given thalidomide maintenance treatment for his disease.
  • DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Leukemia, Plasma Cell / drug therapy. Tachycardia, Ventricular / chemically induced. Thalidomide / adverse effects

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037876.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


95. van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ: Identification of primary MAFB target genes in multiple myeloma. Exp Hematol; 2009 Jan;37(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20).
  • These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene.
  • RESULTS: The inducible cell lines identified a total of 284 modulated transcripts.
  • These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.
  • [MeSH-minor] Cell Line. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 21 / metabolism. Gene Expression Profiling. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / metabolism. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-maf / genetics. Proto-Oncogene Proteins c-maf / metabolism. Quantitative Trait Loci / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013005.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / MAF protein, human; 0 / MAFB protein, human; 0 / MafB Transcription Factor; 0 / Proto-Oncogene Proteins c-maf
  •  go-up   go-down


96. Muñoz A, Riber C, Trigo P, Castejón F: Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders. J Equine Sci; 2009;20(4):59-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukemia, i.e., the neoplasia of one or more cell lines of the bone marrow, although less common than in other species, it is also reported in horses.
  • Leukemia can be classified according to the affected cells (myeloproliferative or lymphoproliferative disorders), evolution of clinical signs (acute or chronic) and the presence or lack of abnormal cells in peripheral blood (leukemic, subleukemic and aleukemic leukemia).
  • The main myeloproliferative disorders in horses are malignant histiocytosis and myeloid leukemia, the latter being classified as monocytic and myelomonocytic, granulocytic, primary erythrocytosis or polycythemia vera and megakaryocytic leukemia.
  • The most common lymphoproliferative disorders in horses are lymphoid leukemia, plasma cell or multiple myeloma and lymphoma.
  • Lymphoma is the most common hematopoietic neoplasia in horses and usually involves lymphoid organs, without leukemia, although bone marrow may be affected after metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24833969.001).
  • [ISSN] 1340-3516
  • [Journal-full-title] Journal of equine science
  • [ISO-abbreviation] J Equine Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4013965
  • [Keywords] NOTNLM ; anemia / blood / clinical pathology / horses / leukemia
  •  go-up   go-down


97. Iino M, Nakajima A, Shindo H: [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2441-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
  • Through hematologic and bone marrow examination, we diagnosed her illness as primary plasma cell leukemia.
  • Afterward, the patient received high-dose cyclophosphamide (4 g/m(2))for hematopoietic stem cell mobilization, and peripheral blood hematopoietic stem cells were collected 14 days later from the start of chemotherapy.
  • Thereafter, the patient received 2 courses of high-dose melphalan (200 mg/m(2)), followed by tandem autologous peripheral blood stem cell transplantation.
  • Taken together, although primary plasma cell leukemia is a rare hematologic malignancy with poor prognosis, the intensive chemotherapy followed by tandem autologous peripheral blood stem cell transplantation may well improve the clinical outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / surgery. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098420.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; VAD combination
  •  go-up   go-down


98. Kar R, Dutta S, Bhargava R, Kumar R, Pati HP: Immunoglobulin free light chains: do they have a role in plasma cell leukemia? Hematology; 2008 Dec;13(6):344-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin free light chains: do they have a role in plasma cell leukemia?
  • The assay of serum free light chains (FLCs) is established in the diagnosis and prognosis of several plasma cell dyscrasias, but its significance in plasma cell leukemia (PCL) has not been reported so far.
  • PCL is a rare and aggressive disease with a poor prognosis.
  • [MeSH-minor] Adult. Aged. Disease Progression. Fatal Outcome. Female. Humans. Kidney Diseases. Leukemia, Plasma Cell. Male. Middle Aged. Paraproteinemias. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055862.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / beta 2-Microglobulin
  •  go-up   go-down


99. Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, Christensson B, Flygare J, Sander B: Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer; 2008 Sep 1;123(5):1025-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endogenous and synthetic cannabinoids exert antiproliferative and proapoptotic effects in various types of cancer and in mantle cell lymphoma (MCL).
  • In this study, we evaluated the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) in non-Hodgkin lymphomas of B cell type (n = 62).
  • In functional studies using MCL, Burkitt lymphoma (BL), chronic lymphatic leukemia (CLL) and plasma cell leukemia cell lines, the stable anandamide analog R(+)-methanandamide (R(+)-MA) induced cell death only in MCL and CLL cells, which overexpressed both cannabinoid receptors, but not in BL.
  • [MeSH-major] Antimitotic Agents / pharmacology. Arachidonic Acids / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Receptor, Cannabinoid, CB1 / metabolism. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Cell Proliferation / drug effects. DNA, Complementary / analysis. DNA, Neoplasm / analysis. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / metabolism. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / metabolism. Mice. Mice, Inbred NOD. Mice, SCID. Mitosis / drug effects. Mitotic Index. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous. Up-Regulation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546271.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimitotic Agents; 0 / Arachidonic Acids; 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / Receptor, Cannabinoid, CB1; 0 / Receptor, Cannabinoid, CB2; 150314-39-9 / methanandamide
  •  go-up   go-down


100. Liebisch P, Eppinger S, Schöpflin C, Stehle G, Munzert G, Döhner H, Schmid M: CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica; 2005 Apr;90(4):489-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Despite recent advances in the treatment of multiple myeloma (MM), this disease remains incurable in the majority of patients.
  • To investigate the applicability of this compound to clonal plasma cell disorders, we analyzed CD44v6 expression on malignant plasma cells from patients with multiple myeloma.
  • DESIGN AND METHODS: Bone marrow samples from 57 patients with monoclonal gammopathy of undetermined significance (MGUS), MM, and plasma cell leukemia (PCL) were examined for CD44v6 expression by using flow cytometry (FACS) analysis.
  • RESULTS: In only 1 of 16 cases (6%) with MGUS and 1 out of 6 cases (17%) with stage I MM were plasma cells CD44v6 positive.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / immunology. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / genetics. Paraproteinemias / immunology. Tumor Burden / immunology






Advertisement